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Baculoviruses (BVs) are rod shaped, double stranded DNA viruses infecting 
insects. They have been engineered to deliver genes into mammalian cells for more 
than two decades now. Because of their large cloning capacity, non-pathogenic 
nature, low cytotoxicity and ease of production, they are emerging as a novel and 
promising gene therapy vector for a number of ex vivo and in vivo applications, 
especially for the treatment of brain tumors and are gearing up to enter clinical trials. 
However, there have been reports that BV elicits immune responses in mammalian 
hosts and undergoes inactivation by serum complement system, thus questioning 
their suitability for clinical trials. Mammalian host responses to baculoviral 
transduction or inoculation is not yet completely known, the understanding of which is 
necessary to overcome the obstacles put forth by the immune system. Hence, this 
study aims to assess the host responses to baculoviral inoculation, particularly in the 
brain and develop methods to attenuate them.  
Foreseeing clinical applications for BV, to substantially reduce unwanted 
immune responses due to insect cell culture derived impurities such as host cell 
DNA, proteins and endotoxins in BV formulations, membrane chromatography based 
baculovirus purification method was improvised. Purified BV formulation was 
checked for host responses in mice brains by cDNA microarray gene expression 
profiling. This purification method yielded highly pure in vivo grade BV formulation 
that induced lesser immune responses in mice brains compared to a commonly used 
laboratory method of high-speed centrifugation to purify BV.  
To investigate the host responses to BV purified by membrane 
chromatography, non-human primates - cynomolgous macaques that share a high 
genomic similarity with humans were used. This is the first study to explore the host 
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response to BV in non-human primates. Analysis of global gene expression profiles 
using cDNA microarray technology upon intracranial administration revealed that rBV 
inoculation caused no major abnormality to the animals but induced anti-viral, 
primarily, innate immune response and complement protein activation as major 
reactions. The humongous data generated from the microarray studies also revealed 
the major pathways of IFN induction in macaque brains thus offering better 
understanding of the primates’ responses to BV and clues to overcome them.  
To overcome the major hurdle of in vivo inactivation of BV by serum 
complement proteins, a novel method of coating rBV with cationic lipids – 
Lipofectamine 2000 and Cellfectin II was developed and tested in vitro. It was 
established that cationic lipid coated BV greatly improved the transduction efficiency 
of BV in the presence of serum though there was not much improvement in the 
absence of serum. These findings together will facilitate the optimization of BV vector 
design and serve as a guide to rational therapeutic applications of BV vectors. 
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1. Introduction 
1.1. Baculoviruses – an overview 
Baculoviruses (BVs) constituting the family Baculoviridae are a very diverse 
group of viruses infecting a wide range of invertebrates of which well documented are 
insects from the orders of Lepidoptera, Dipteria and Hymenoptera. They possess 
double stranded, super-coiled, circular genomes with sizes varying from 80 kb to 
over 180 kb  packed into rod shaped nucleocapsids of dimensions 230-385 nm x 40-
60 nm (Rohrmann, 2011b). Discovered as early as 5000 years ago when the silk 
industry originated, BVs initially received interests because of the threat they posed 
to the silk industry. Later, in 1980s, when it was first demonstrated that BVs can be 
genetically modifed to carry genes of interest, they moved in to the main stream of 
biotechnology for three main reasons. The inherent insecticidal activity of baculovirus 
together with recombinant technology have been exploited in making insecticides 
with enhanced host specificity and killing speed marking a new era in insect selective 
peptide toxin (Inceoglu et al., 2006). Together with insect cells that support post 
translational modifications similar to that in mammalian cells, BV has been utilised to 
make recombinant proteins that serve as vaccines and therapeutics (Drugmand et 
al., in press). Non-replicative nature of BV in mammalian cells together with the wise 
use of promoters has been taken advantage of to develop them as gene delivery 
vectors to a number of mammalian cells and animal models (Hu, 2006). Of these 
varied applications, this section shall focus on the dimension of BV as a gene 
delivery vector gearing up to enter clinical trials. 
More than 20 unique BV genomes have been sequenced so far. The best-
characterized BV, Autographa californica multicapsid nucleo-polyhedrosis virus 
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(AcMNPV) has a genome of 134kb and is estimated to contain 154 genes. BV genes 
are expressed in a transcriptional cascade where each phase is dependent on the 
expression of genes in immediate previous phase. Generally, they can be divided 
into two categories, early genes, which are transcribed by the host RNA polymerase 
and late genes which are transcribed by a virus-specific RNA polymerase. 
Expression of late genes is completely dependent on the expression of early genes 
and is indispensible for the expression of two very late genes, namely polyhedrin 
gene, which encodes the major occlusion body protein, and p10, which encodes a 
small poorly conserved protein that may be involved in occlusion body formation or 
cell lysis. These two proteins are highly expressed due to very strong promoters but 
are not really necessary for infectious virus formation. Replacing these genes with 
foreign genes appended to suitable mammalian cell promoters convert these viruses 
into expression vectors for recombinant protein production and therapeutic gene 
delivery (summarized from Ahrens C H, 1996, Okano et al., 2006, Vlak, 2008). 
1.2. Fate of baculovirus (BV) 
Baculoviruses being insect viruses, their fate in insect cells is different from 
that in mammalian cells. It is these differences that are used to the advantage of the 
researchers to develop them as promising gene delivery vectors that awaits entry 
into clinical trials.  
1.2.1. In insect cells 
In insect cells, BVs follow a complex replication cycle involving two types of 
virions. One is occluded virus (OV) adapted for stability outside the host and for 
infection of the insect midgut cells. Other is the budded virus adapted for cell to cell 
and systemic infection within the host. Based on the morphology of their occlusion 
bodies, BVs can be divided into two major genera – nucleopolyhedrosis viruses 
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(NPVs) characterised by single or multiple virions occluded in polyhedrins and 
granuloviruses (GVs) characterized by single virion occluded in granulin matrix. 
When both genera are widely used as insectides, NPVs are majorly researched as 
gene delivery vectors. Especially Autographa californica multiple nucleopolyhedrosis 
virus (AcMNPV) is revered as widely used gene delivery vector. Upon consumption 
by insects, once inside the midgut, OVs are sensitive to the alkaline insect gut fluid 
containing enzymes that break down the crystalline protein matrix and release the 
occluded virions called occlusion-derived virions (ODVs). The released ODVs fuse 
with the midgut cells releasing nucleocapsids and initiating viral replication. During 
the early stage of infection, nucleocapsids bud through the plasma membrane to 
form budded viruses. These budded viruses help spread the viral infection through 
out the insect. During the later stage of infection, i.e. about 5-7 days after ingestion, 
OVs are formed. After the insect dies, the OVs are ready to infect other larva 
(summarized from Inceoglu et al., 2006, Rohrmann, 2011a). This is summarized in 





Figure 1.1. Fate of BV in insect cells. (A) Occlusion bodies ingested by an insect 
dissolve in the alkaline environment of midgut to release ODVs which then infect 
midgut cells (B) Virions bud out of the cell to initiate infection (C) Early stage infection 
where more budded viruses are produced to spread the infection through out the 
insect (D) Late stage infection where virions are occluded and the cell dies releasing 
them. Image adapted from Rohrmann, 2011a. 
1.2.2. In mammalian cells 
In mammalian cells, BVs cannot replicate because of the transcriptional 
silencing of its major regulatory genes. Unlike in insect cells, occluded viruses have 
no role in mammalian cells. It is the budded baculoviruses accomodating transgenes 
harvested from insect cells that are used as gene delivery vectors for mammalian 
cells. Baculovirus entry into mammalian cells is not yet clearly understood. There are 
evidences for several of the factors and several routes to be involved in its entry. For 
instance, while Duisit et al showed that the entry depended on electrostatic 
interactions and heparan sulfate (Duisit et al., 1999), Tani et al demonstrated it to 
depend on phospholipids (Tani et al., 2001). Clathrin dependent (Matilainen et al., 




macropinocytosis (Matilainen et al., 2005) and phagocytosis (Laakkonen et al., 2008) 
have been demonstrated to be the routes of entry. These diverse data suggest that 
BV might follow different entry routes depending on the cell type. Nevertheless, there 
is a unified notion that the envelope glycoprotein gp64 is essential for its entry as 
blocking it abrogated the transduction efficiency of BV (Abe et al., 2005, Niu et al., 
2008) and also its capacity to activate dendritic cells (Schutz et al., 2006). 
Once inside the cell’s endosome, triggered by the pH change, gp64 fuses 
with the endosomal wall delivering the contents of BV into cytoplasm which is then 
transported to the nucleus where the transgene is transcribed. With the right kind of 
promoters that support replication in mammalian cells, baculoviruses are known to 
express a wide variety of transgenes (Hu, 2006, Chen et al., 2011). This is illustrated 
elaborately in Figure 1.2. Out of the 155 genes that BV codes for, 43  transcripts 
have been detected in BV transduced Hela cells using BV DNA chips (Fujita et al., 
2006, Liu et al., 2007) and overexpression of immediate early genes ie1 and ie2 
increased the number of activated transcripts to 59 in mammalian Vero E6 cells (Liu 
et al., 2007). Also, three immediate early genes from another baculovirus 
Bombyx Mori NPV, BmNPV, were activated in transduced HEK 293 cells (Kenoutis et 
al., 2006). However, there have been no reports of baculovirus replicating in 




Figure 1.2. Fate of BV in mammalian cells. Illustrated is the proposed entry and 
intracellular trafficking of a baculovirus vector for expression of a therapeutic gene in 
a mammalian cell. Image adapted from Hu, 2006.  
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1.3. Advantages of BV in comparison with other gene delivery vectors 
Gene delivery vectors can be broadly classified into non-viral and viral 
vectors. Non-viral vectors include nucleotide or amino acid sequences either naked 
or coated with artificially synthesized cationic lipids or polymers. Though they have 
low immunogenicity, they are often restricted by the poor transduction efficiency 
(Boeckle et al., 2006). Viral vectors possess the capacity of high transduction 
efficiency and the flexibility to be genetically modified to attain target specificity. 
Some of the commonly used viral vectors include retroviruses (RV), lentiviruses (LV), 
adenoviruses (Ad) and adeno-associated viruses (AAV). Though several of these 
vectors are already in clinical trials (Edelstein et al., 2007), they are not without 
limitations. For instance, the life cycle of retroviruses include an integrated state in 
the host genome that allows for long-term, stable expression of therapeutic genes. 
The preferential integration of these vectors into transcriptionally active regions of 
host genomes, however, occassionally leads to insertional mutagenesis, oncogene 
activation and cellular transformation, the most severe case being the development 
of leukemia in several children in France and the UK following RV gene therapy for 
SCID-X1 (Hacein-Bey-Abina et al., 2003). Lentiviruses derived from human or simian 
immunodeficiency viruses (HIV or SIV) are emerging as capable gene delivery 
vectors for dividing and non-dividing cells. However, the pathogenic nature of HIV or 
SIV does not eliminate the safety concerns associated with their usage. Ad and AAV 
derived viral vectors have a much lower risk of insertional mutagenesis. However, as 
infectious human viruses, both can activate the human immune system (Jooss et al., 
2003, Bessis et al., 2004, Huang et al., 2009). This is of serious concern in view of 
the possible undesired rejection responses. Pre-existing immunity against adenovirus 
has been detected in the majority of the human population (Jooss et al., 2003, Nayak 
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et al., 2010) and in a worse case, this has brought about death following fever and 
multiple organ failure in an individual who was treated for ornithine transcarbamylase 
partial deficiency with a high dose of adenoviral vector (Bostanci, 2002, Thomas et 
al., 2003). Pre-existing immune responses to AAV vectors are no less than that to Ad 
vectors (Thomas et al., 2003). AAV vectors are efficient in activating B cells (Bessis 
et al., 2004) and specific antibodies against AAV2 are detected in 35 to 80% of 
individuals depending on age group and geographic location (Jooss et al., 2003). The 
unfortunate death events have brought intense scrutiny to the potential risk 
associated with the viral vectors. Even if the pre-existing antiviral immunity does not 
trigger severe pathological changes, it can still inactivate the viral vectors, therefore 
affecting their transduction efficiency. The demerits of various gene transfer vectors 
in dealing with safety and efficacy underscore the importance of the development of 
new vectors. 
In comparison with these vectors, BVs have numerous advantages. The most 
commonly used BV vectors are derived from Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV) and for this reason, all through out this thesis, 
AcMNPV are commonly refered to as BV. As mentioned earlier, BV has the ability to 
enter mammalian cells and express the transgene but, it neither replicates inside the 
transduced cell nor causes obvious toxicity to the cell (Kost et al., 2005). The viral 
DNA degrades over time thus eliminating the possibility of causing side effects to the 
host cells (Ho et al., 2005, Wang et al., 2005b). The vector has a high cloning 
capacity (at least 38 kb) allowing accommodation and delivery of a large functional 
gene or multiple genes (Cheshenko et al., 2001). Unlike many other gene therapy 
viral vectors, BVs can be produced in serum-free cell culture medium, which 
eliminates the potential hazard of serum contamination with viral and prion agents 
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from the donating animal. Most importantly, BVs do not have pre-existing antiviral 
immunity in humans since it is not infectious to them. Strauss et al. have reported 
that none (n=20) of the serum samples tested positive for BV neutralizing antibodies 
while 65% of the samples tested positive for Ad type 5 (Strauss et al., 2007). In the 
same study, pre-existing Ad-specific T cells were detectable but there were no pre-
existing BV-specific T cells in humans. Thus, BV has relatively low immunogenicity 
as indicated by the induction of lesser number of virus-specific T-cells (Strauss et al., 
2007). All these advantages and safety associated with BV have been motivating the 
increasing efforts to employ it for a wide range of applications. 
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Table 1.1. Viral vectors for gene therapy. Adapted from Kim et al., 2009a. !
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1.4.  Applications of BV as a gene delivery vector 
Since the first finding in 1995 that BV can transduce mammalian cells, a 
number of studies have demonstrated their capacity to deliver genes in vivo. For 
instance, BV could successfully deliver genes into carotid artery of rabbits (Airenne et 
al., 2000), liver (Huser et al., 2001) and brain (Sarkis et al., 2000, Lehtolainen et al., 
2002, Wang et al., 2005a) of rats, as well as brain (Sarkis et al., 2000), skeletal 
muscle (Pieroni et al., 2001), cerebral cortex, testis (Tani et al., 2003), liver (Hoare et 
al., 2005) and brains of mice (Balani et al., 2009, Wu et al., 2009). In vivo gene 
delivery testing phase using reporter genes was soon replaced by therapeutic gene 
delivery. The following paragraphs will briefly discuss the therapeutic applications of 
BV gene delivery in in vivo studies. 
1.4.1. In vivo studies involving direct injection 
Cancer therapy is one of the major areas in which BV has been widely 
evaluated for its gene delivery and therapeutic efficacy. The suitability of BV for 
cancer gene therapy was first demonstrated in 2006 when recombinant baculovirus 
(rBV) expressing bacterial diphtheria toxin A (DT-A) gene impeded the growth of 
cultured mouse and human glioma cells and glioma xenograft in immune-competent 
rat brains (Wang et al., 2006a). Following that, rBV expressing HSVtk governed by a 
truncated high mobility group box2 (HMGB2) promoter suppressed the growth of 
human glioblastoma xenograft in the presence of the prodrug ganciclovir (GCV) and 
extended the survival in mice models. HMGB2 restricted the expression of the 
suicide gene to the glioma cells thus minimizing the damage to neighboring cells 
(Balani et al., 2009). Alternatively, GFAP promoter active in normal and glioma cells 
was used to govern the HSVtk gene and the target specificity of BV was improved by 
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exploiting the idea of transgene regulation by endogenous micro RNAs (miRNA) 
(Brown et al., 2006, Brown et al., 2007). Target sequences of three miRNA (has-
miR31, has-miR127 and has-miR143) that were down-regulated in gliomas but not in 
normal glial cells and neurons were appended to the 3’ end of HSVtk gene to restrict 
the expression of tk to glioma cells. In the presence of GCV, this rBV effectively 
inhibited human glioma xenograft and imparted negligible toxicity to normal 
astrocytes (Wu et al., 2009).  
rBV could successfully deliver a number of tumor suppressor and apoptotic 
genes to arrest the solid-tumor growth and induce apoptosis. For instance, rBV has 
been used with tumor suppressor genes, p53 to inhibit the growth of U251 glioma cell 
induced subcutaneous tumors, normal epithelial cell specific gene-1 (NES1), to treat 
gastric cancer (Huang et al., 2008b) and programmed cell death 4, Pdcd4 to 
suppress the growth of oral squamous carcinoma xenografts (Kim et al., 2010) and 
apoptotic protein, apoptin to suppress the growth of hepatocellular carcinoma in mice 
models (Pan et al., 2010). Recently, BVs have been used to inhibit angiogenesis, the 
process of formation of new blood vessel that is indispensible for the growth and 
spread of tumors. Hu and colleagues constructed rBVs accommodating anti-
angiogenic fusion protein hEA (human endostatin and angiostatin) with/without 
inverted terminal repeat (ITR) sequences from adeno-associated virus (AAV). In vivo, 
rBV-hEA with AAV-ITR resulted in stronger angiogenic effects, potent tumor growth 
inhibition and prolonged the survival of mice with pancreatic xenograft compared to 
control treated mice and rBV-hEA with no ITR treated mice (Luo et al., 2011b). 
Alternatively, rBV constructed with a hybrid sleeping beauty (SB) transposon not only 
hindered the growth of prostate tumor allografts and human ovarian tumor xenografts 
and extended the survival of animals by inhibiting angiogenesis in vivo but also 
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prolonged the expression up to 77 days without any antibiotic selection (Luo et al., 
2011a). 
rBV has also been used to deliver immunogenic molecules thus marking a 
niche for itself as vaccine for a number of animal and human diseases (Madhan et 
al., 2010) including cancer (Wang et al., 2010a). The concept of baculovirus as a 
vaccine vector was first described by Aoki et al (Aoki et al., 1999) when intramuscular 
immunization of recombinant baculovirus expressing rabies viral glycoprotein B 
induced antibody response specific to that protein. Following that, in 2007, Kim et al 
demonstrated the potential of a pseudotyped baculovirus expressing mTERT, a 
potential tumor associated antigen (TAA) driven by CMV promoter as an anti-cancer 
gene delivery vaccine (Kim et al., 2007) for GL26 glioma cell challenge in mice.  
Baculoviruses engineered to express antigens on their surface are much more potent 
in eliciting antigen-specific immune responses than those that express immunogenic 
molecules upon transduction. The capsid protein VP39 and viral envelope 
glycoprotein gp64 are the most commonly exploited proteins for this purpose. 
Recently, BV engineered to express a fragment of ovalbumin (OVA) on the capsid 
protein VP39 was found to have adjuvant activity and efficiently deliver OVA antigens 
to potentiate anti-tumor immune response in melanoma mice models (Molinari et al., 
2011). Several different antigens have been expressed as a fusion protein with gp64 
and have proved successful as vaccines against infections by foot and mouth 
disease virus, Plasmodium berghei, malaria, H5N1 and bovine herpesvirus-1 (BHV-
1) (Madhan et al., 2010). However, the efficiency of this site for TAA display remains 
unexplored. Also, the natural immunogenicity of BV that elicits non-specific immune 
responses have certified them as adjuncts for antiviral and anti-tumor therapies 
(Kitajima et al., 2008). 
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1.4.2. Ex vivo transduction of cells by BV for cancer therapy and regenerative 
medicine 
Besides being directly used as gene delivery vectors, rBVs have been used to 
transduce cells ex vivo and used in cell-based cancer therapies and tissue and bone 
regeneration. Bone marrow-derived DCs (BMDCs) transduced with wild type 
baculovirus ex vivo and administered intravenously suppressed the growth of  lung 
cancer and melanoma in mouse models and improved their cell survival. The anti-
tumor activity could be contributed partly to the induction of CD8+ T cell- and NK cell-
dependent, CD4+ T cell-independent antitumor immunity. Interestingly, the 
intravenous injection did not bring about significant damage to the liver and kidney as 
revealed by the minimal disturbance to the serum alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and creatine levels (Suzuki et al., 2010). Other 
cells used in cancer therapy and at the same time possessing tumor tropism are 
stem cells like mesenchymal stem cells (MSCs) and neural stem and precursor cells 
(NSCs/NPCs) that respond to inflammatory mediators secreted from tumor cells and 
migrate to tumor tissues. These stem cells engineered to carry therapeutic genes 
have been exploited for delivering gene products to main tumor mass as well as 
metastatic tumors. BV vectors have not only been demonstrated to successfully 
transduce stem cells, including human embryonic stem cells (hESCs) (Zeng, 2007, 
Du et al., 2010), hESC derived stem cells (Zhao et al., 2011), and human bone 
marrow-derived MSCs (BMSCs) (Ho et al., 2005, Ho et al., 2006) without significant 
changes in their stemness and characteristics but exhibit cancer therapeutic efficacy. 
Tail vein injection of BMSCs transduced with BV expressing HSVtk significantly 
repressed human glioma xenograft in the presence of GCV and prolonged the 
survival of animals (Bak et al., 2010). BV-tk transduced MSC like cells (Bak et al., 
2011) and NSC like cells (Zhao et al., 2011) derived from hESCs also exhibited 
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similar therapeutic effect on glioma bearing mice models in the presence of GCV and 
extended the survival of tumor bearing mouse. BVs have also been used to direct 
BMSCs differentiation ex vivo into specific lineage by delivering appropriate growth 
factors. For example, BMSCs transduced with BV accommodating bone 
morphogenic protein-2 (BMP-2) differentiated into osteoblasts in vitro (Chuang et al., 
2007). Administration of these cells into mice (Chuang et al., 2007) and rats (Chuang 
et al., 2010) resulted in progressive mineralization and ectopic bone formation. BVs 
have also been used to transduce adipose-derived stem cells (ASCs), another 
promising stem cell source for regenerative medicine (Lo et al., 2009). ASCs 
requiring sustained expression of growth factors promoting osteogenesis and 
angiogenesis for successful differentiation into osteoblasts were transduced with dual 
baculoviral vector system containing flippase recombination enzyme in one and bmp-
2 or vegf in another flanked by the flippase recognition target sequences to acquire 
persistent gene expression for more than 28 days. BV transduced ASCs accelerated 
the healing, improved the bone quality and angiogenesis for repairing large 
segmental bone defects (Lo et al., 2009).  
1.4.3. Other applications 
Apart from applications as vaccines and cancer gene delivery vectors, BV, 
because of its efficient gene delivery have found use as RNA interference mediator. 
BV mediated delivery of shRNA has been shown to effectively inhibit the replication 
of porcine reproductive and respiratory syndrome virus (PRRSV) (Lu et al., 2006), 
peste des petits ruminants virus (PPRV) (Nizamani et al., 2011) and Hepatitis B virus 
(HBV) (Starkey et al., 2009) in vitro.  BV mediated miRNA delivery has also been 
demonstrated to knock down the target gene in vitro thus implicating their potential 
for antiviral therapy (Chen et al., 2011). Also, several recombinant proteins produced 
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in baculovirus expression vector system (BEVS) are being tested in clinical trials as 
vaccines with Cervarix® (a product of GSK) managing to reach the market first as an 
effective prophylactic vaccine for cervical cancer and other HPV infections. Cervarix 
is a formulation of L1 proteins from human papilloma viruses (HPV) 16 and 18 
produced in BEVS and ASO4, an adjuvant containing 3-O-desacyl-4'- 
monophosphoryl lipid A (MPL) adsorbed on aluminium hydroxide and hydrated 
(Al(OH)3). Cervarix gives rise to better immunogenicity by inducing higher serum 
neutralizing antibody titers and has a safe profile on patients compared to the 
GARDASIL (a product of Merck), another vaccine containing L1 proteins produced in 
yeast for HPV infections and cervical cancer (Einstein et al., 2009). Another product 
with proteins raised in BEVS is the vaccine Provenge for advanced, metastatic, 
asymptomatic hormone refractory prostate cancer (HRPC) that is recently approved 
by the US FDA. Provenge is a product of Dendreon Corporation consisting of 
autologous dentritic cells (DCs) loaded ex-vivo with a recombinant fusion protein 
consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage 
colony-stimulating factor produced in BEVS. Shortly after FDA approval, Provenge 
was added to compendium of cancer treatment published by National 
Comprehensive Cancer Network as the highest recommended drug for HRPC. 
1.5. Host responses to BV 
Despite all these successes as a gene delivery vector, BV has certain 
limitations that delay its advancement into clinical trials. Among them, the most 
crucial are the host immune responses to BV, susceptibility of BV to the host 




1.5.1. Immune responses to BV 
BV is capable of eliciting immune responses in mammalian cells and 
conferring antiviral and anti-tumor protection in animal models. This has been 
exploited in making vaccines. However, only a few definitive findings have been 
reported on such use. In vitro, in mammalian cells, they have been demonstrated to 
induce the expression or promote the release of inflammatory cytokines including 
interferons (IFNs), tumor necrosis factor – alpha (TNF-α), interleukin (IL)-1α, IL-1β, 
IL-6, IL-8 and IL-12 (Abe et al., 2010). In vivo, they could elicit significant innate 
immune responses which were exploited to protect animals from lethal 
encephalomyocarditis virus (Gronowski et al., 1999) and influenza virus (Abe et al., 
2003). They can also stimulate natural-killer (NK) cell mediated increase in serum 
levels of IFN-γ that is involved in antiviral and antitumor effects and demonstrate 
antitumor immunity (Kitajima et al., 2008). Apart from cytokine production, they can 
activate mouse dendritic cells (DCs) through their interaction with Toll-like receptor 9 
(Abe et al., 2005) and also human DCs (Schutz et al., 2006) thus leading to the 
induction of adaptive immunity. They were also demonstrated to potentiate adaptive 
immune responses by inducing IFN-α and IFN-β (Hervas-Stubbs et al., 2007). 
Previous studies from our lab demonstrated that BV could mount immune responses 
in “immune privileged” brains in rats by activating the TLR signaling pathway and IFN 
α/β signaling pathway (Boulaire et al., 2009). However, the precise mechanism of 
elicitation of immune responses by BV remains unclear. A clear understanding of this 
is essential to make maximal use of the advantageous and promising baculovirus as 
gene delivery vectors. 
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1.5.1.1.  Components of BV responsible for eliciting immune responses 
Given the production of proinflamatory cytokines and type I IFNs upon BV 
administration, they are believed to possess immuno-stimulatory capacity. However, 
the exact component responsible for immune stimulation is not yet known. 
Grownowski et al demonstrated that only live BV could elicit immune responses but 
not the inactivated BV or dsRNA, DNA or lipopolysaccharides derived from BV 
preparation (Gronowski et al., 1999). Particularly, gp67, probably identical to gp64 
was shown to be responsible for the IFN production in cultured cells and protection 
from a lethal encephalomyocarditis virus infection in mice. Addition of monoclonal 
antibodies raised against gp67 bound to them tightly and neutralized their IFN 
inducing capacity (Gronowski et al., 1999). As mentioned previously, the envelope 
glycoprotein gp64 is believed to play a major role in the entry of BV into mammalian 
cells. Since BV is amplified in insect cells and proteins derived from insect cells do 
not pass through N-linked oligosaccharides to form complexes containing outer-chain 
galactose and sialic acid residues, gp64 contains mannose, fucose and N-acetyl 
glucosamine but no detectable galactose or terminal sialic acid residues like those in 
mammalian cell derived proteins (Jarvis et al., 1995). Mannose receptors are 
primarily expressed on the immune competent cells like macrophages and dendritic 
cells and play a key role in host defense and induce an innate immune response. It is 
suggested that the mannose residues on gp64 may be recognised by the mannose 
receptor (MR) and contribute to the immune responses. However, Abe et al 
demonstrated that recombinant gp64 produced in insect cells produced no pro-
inflammatory cytokines and type-I IFNs in mouse macrophage cell lines (Abe et al., 
2005) suggesting that viral component other than gp64 may participate in the 
immune activation by BV. The same study also demonstrated that the genomic DNA 
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of BV with amounts of bioactive CpG sequences similar to that in E.coli or herpes 
simplex virus (HSV) was recognized by the pathogen recognition receptors (PRRs), 
toll-like receptors (TLRs) or TLR independent cytoplasmic recognition (Abe 2005 and 
2009). Another study by Jordan et al demonstrated that BV infected insect cells 
expressing MHC peptide complexes have been recognised, processed and 
presented by host antigen presenting DCs which further generate functional antigen 
specific CD8+ T cell responses (Jordan et al., 2008). This emphasizes the 
contribution of unwanted insect cells and proteins to the elicitation of immune 
responses by the host. Thus, several components of BV formulation are known to 
elicit immune responses. 
1.5.2.1. Involvement of various PRRs in IFN production upon BV recognition 
TLRs 
Once inside the immune competent cell, BVs are recognized by pathogen 
recognition receptors (PRRs) like membrane bound toll-like receptors (TLRs) and 
cytoplasmic RIG-1 like receptors (RLRs). TLRs are the most well studied PRRs with 
respect to viral infections (Kawai et al., 2008). Upon infection, TLRs follow MyD88 
dependent pathway to activate NFkB and c-Jun, the transcriptional regulators of a 
number of chemokines and cytokines responsible for cellular immune response 
(Wang et al., 2001). BVs are known to induce type I interferons (IFNs) in immune 
cells like peritoneal macrophages (PECs), splenic CD11c+ DCs and murine 
macrophage line RAW264.7 through TLR-9/MyD88-dependent pathway (Abe et al., 
2005). However, IFN production was not completely restricted upon BV inoculation in 
cells derived form MyD88 or TLR-9 deficient mice or in PECs treated with endosomal 
inhibitors, suggesting the existence of TLR-9 and endocytosis independent signaling 
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pathways (Abe et al., 2005, Abe et al., 2009). Recently, Chen and colleagues 
reported that BVs can induce type I IFN production in mesenchymal stem cells 
through TLR-3 dependent pathway (Chen et al., 2009a). Our laboratory has 
demonstrated through microarray studies that neurons, which do not possess TLR-9, 
respond to BV transduction by inducing IFN signaling pathway involving STAT1 and 
STAT2 through TLR-3 dependent pathway. In rat brains, TLR2 is involved in IFN 
production (Boulaire et al., 2009).  
RLRs 
RLRs are a second class of PRRs including RNA helicases like RIG-1, MDA5 
and LGP2 that reside in the cytoplasm of immune and non-immune cells and 
recognize viral dsRNA species produced in the cytoplasm. RLRs are known to induce 
type I IFN production through an adaptor molecule IPS-1 that localizes in the 
mitochondria (Kawai et al., 2005). LGP2 serves as a negative or positive regulator of 
RIG-1 and MDA-5 depending on the type of RNA viruses (Venkataraman et al., 
2007). Though not many studies have demonstrated the involvement of RLRs in BV 
transduction, a recent study has noted that RIG-1 and MDA5 mRNA levels were 
elevated in BV-transduced cells (Wang et al., 2010b). Involvement of RLR signaling 
pathway in BV transduction is a relatively new field ready for exploration.  
Cytosolic DNA sensors 
Apart from TLR and RLR signaling pathways, there are evidences for other 
pathways involving cytosolic DNA sensors to participate in IFN production. Recently, 
Abe et al, upon examining the molecular mechanism of type I IFN induction by BV in 
a number of immune and non-immune cells found that type I IFN production in PECs 
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was TLR independent but did not involve RLRs. At the same time, pretreatment with 
endocytosis inhibitors did not affect the IFN production significantly suggesting the 
involvement of cytoplasmic recognition of BV by TLR-independent immune sensors 
(Abe et al., 2009). Recently, several receptors for cytoplasmic DNA sensors such as 
DNA-dependent activator of IRFs (DAI) and stimulator of IFN genes (STING) have 
been identified to play roles in IRF3 activation and thus IFN production in response to 
dsNDA derived from viruses, bacteria and synthetic analogues (Takaoka et al., 2007, 
Ishikawa et al., 2008, Zhong et al., 2008) Though interrupting the function of DAI 
produced sufficient amounts of type I IFN in response to bacterial DNA and synthetic 
B-form DNA (Charrel-Dennis et al., 2008, Ishii et al., 2008), MEFs deficient in STING 
that positively regulates RLR mediated type I IFN production suffered severe 
impairment in IFN production (Ishikawa et al., 2009). These studies suggest a role for 
the cytoplasmic DNA sensors DAI and STING in type I IFN induction.  
Though these immune responses are used to the advantage of researchers in 
making vaccines against a number of human and animal diseases (Madhan et al., 
2010), there are evidences that these immune responses interfere with the transgene 
expression. For example, intramuscular injection of BV in mice stimulated the 
production of neutralizing antibodies and this is suspected to be the reason for 
clearance of transduced muscle fibers (Pieroni et al., 2001). Also there are chances 
for these immune responses to further prevent efficient transduction upon repeated 
injections of BV. The effect of immune responses on transduction upon repeated BV 
administration is yet to be studied.  
1.5.2. BV susceptibility to complement-mediated lysis 
A major hurdle to in vivo BV transduction is its inactivation as a consequence 
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of virus recognition by complement proteins, a major component of innate immune 
system. BV activates both classical (Hofmann et al., 1998) and alternate (Hoare et 
al., 2005) pathways of the complement system and naturally occurring IgM 
antibodies with affinity for BV may be partially responsible for complement activation 
(Hoare et al., 2005).  Activation of the complement system leads to the inactivation of 
viruses or the lysis of infected cells. In the case of virus-based gene transfer, 
activation of the complement system can dramatically reduce gene transfer efficiency 
and occassionally eliminate transgene expression. Sometimes, excessive 
complement activation can result in serious tissue damage and systemic 
inflammatory responses (Kiang et al., 2006). To overcome the barrier imposed by the 
complement system to BV-mediated in vivo gene transfer, immune privileged organs 
that possess intrinsic ability to prevent the activation of innate and adaptive immune 
responses were chosen. These include brain, eye and testis (Simpson, 2006). BV 
administration by stereotaxic injection into the brain (Sarkis et al., 2000, Lehtolainen 
et al., 2002, Tani et al., 2003, Li et al., 2004, Li et al., 2005, Wang et al., 2005a, Liu 
et al., 2006, Wang et al., 2006b), intrathecal injection into the spinal cord (Wang et 
al., 2005c) subretinal injection (Haeseleer et al., 2001) and intravitreal injection 
(Haeseleer et al., 2001, Li et al., 2004, Luz-Madrigal et al., 2007) into the eye and 
injection via the efferent ductules that resulted in efficient transgene expression in 
basal and Sertoli cells of the testis (Tani et al., 2003)serve as examples for this 
strategy.  
BV was also genetically manipulated to accommodate the complement-
regulatory protein human decay-accelerating factor (DAF) incorporated into its 
envelope, which improved the efficiency of BV transduction in complement-sufficient 
neonatal rats after direct injection of the viruses into the liver parenchyma (Huser et 
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al., 2001). However, the presence of DAF protein in the envelope interfered with the 
BV replication cycle and the systemic use of the modified virus was not reported 
(Tani et al., 2003, Hoare et al., 2005). BVs possessing vesicular stomatitis virus 
envelope glycoproteins (VSV-G) were also produced for this purpose. Although these 
viruses exhibited greater resistance to inactivation by animal sera than unmodified 
BV in vitro, there was no detectable transgene expression following injection of VSV-
G pesudotyped BV into mice by the intravenous, intraperitoneal, or intrahepatic route 
(Tani et al., 2003). Another approach is to inhibit the complement proteins at the site 
of BV injection. Co-administration of the soluble complement inhibitor 1 (sCR1) with 
intraportal injection of BV vectors led to a small amount of transgene expression in 
the liver parenchyma, but no detectable transgene expression after tail vein injection 
(Hofmann et al., 1999, Hoare et al., 2005). Other inhibition strategies that were able 
to increase the survival of BV include treatment of human serum with cobra venom 
factor that inhibits the complement component C3 and a functional antibody blocking 
complement component 5 (C5) that are involved in both classical and alternative 
pathways (Hofmann et al., 1998).  
Chemical modification offered another promising approach to overcome the 
problem of complement inactivation. Previous studies have reported enhancement of 
transgene expression when synthetic polymers were used to modify adenoviral 
vectors, retroviral vectors and AAV vectors. As demonstrated in adenovirus, 
modification with synthetic polymers reduces innate immune responses, evades pre-
existing anti-Ad antibodies, and allows for repeated vector delivery, thus serving as 
an effective strategy in overcoming barriers to in vivo delivery of viral vectors 
(Kreppel et al., 2008). It is worth investigating in future whether polymer modification 
of BV can reduce immune recognition, thus allowing a significant level of transgene 
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expression upon repeated administration of BV vectors. 
1.5.3. Purification and concentration of active viral particles 
In vivo gene therapy demands highly pure, heavy doses of viral vectors to 
achieve therapeutic effects, necessitating the development of efficient scalable 
purification and concentration methods. Current purification and concentration 
methods for BV involve ultracentrifugation of virus supernatants harvested from the 
insect cell culture. Budded BV obtains its envelope and glycoprotein gp64, a protein 
enabling infection and transduction of BV, from the host insect cell membrane and 
these lipid and protein components are vulnerable to mechanical forces. The high 
speed associated with ultracentrifugation causes a significant loss of virus infectivity 
due to the damage of viral envelope by hydrodynamic shear stress and often results 
in badly aggregated viral particles. Another limitation with ultracentrifugation 
procedure is the small volume capacity of ultra-high speed rotors, making the scale 
up process difficult.  
Chromatography-based purification schemes are viewed as the most versatile 
methods for virus purification and concentration, with a great potential for large-scale 
manufacturing of high-purity virus stocks for clinical applications (Burova et al., 2005, 
Segura et al., 2006). Several chromatographic methods have been reported for 
concentrating and purifying BV vectors. However, the peculiar rod shape of BV, 
unlike the usual spherical or hexagonal shape of other viral vectors makes its 
recovery from the column very difficult. A cation exchange column based 
chromatographic method used to concentrate baculovirus earlier in 1999 reported a 
recovery rate close to 79% of the starting viruses (Barsoum, 1999). In a method 
using immobilized metal affinity chromatography, BV was modified to display 
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hexahistidine (His6) tags on the envelope so that the tagged viruses can be purified 
by the affinity chromatography (Hu et al., 2003). The purity was up to 87% but the 
recovery by this method was only 2-3%. When a size exclusion chromatography 
method was used, a final virus recovery of 25% was achieved (Transfiguracion et al., 
2007). However, the purity of the BV preparation obtained by this method was 
significantly lower than sucrose gradient purified viruses. More recently, Con A 
chromatography has been used for BV purification (Chen et al., 2009b). As 
baculovirus is strongly bound to the column, >99% of protein impurities can be 
washed away, achieving 16% of recovery after elution. Another new process 
comprises three steps for BV purification - depth filtration, ultra/diafiltration and 
membrane sorption achieving the recovery yield of 40% and the purity over 98% 
(Vicente et al., 2009). We have developed a scalable cation exchange membrane 
chromatographic method to purify BV (Wu et al., 2007). The procedure allowed for a 
final recovery of 78% of infective viral particles from the original supernatant with 
satisfactory purity. Membrane chromatography characterized by faster flow rates and 
easy scalability promises further investigation for scale-up of our method. 
1.6. Aims and Objectives 
Having discussed the major limitations of BV that pose problems for them 
entering clinical trials, the need for more studies to address these issues can be 
realized. Therefore, the aim of this thesis is to understand the host responses to BV 
inoculation in brains of animal models, especially non-human primates that better 
reflect the human responses and develop methods to reduce them or mask BV from 
the host immune system. Three lines of investigation were pursued in this study. 
1. In chapter 3, membrane chromatography based method to purify BV was 
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improvised to obtain in vivo grade BV formulation. The method was validated for 
reducing immune responses in mice brains compared to a high speed centrifugation 
method by high throughput cDNA microarray gene expression profiling. 
2. In chapter 4, the host responses to BV purified by membrane 
chromatography method was evaluated by high throughput cDNA microarray gene 
expression profiling in non-human primates’ brains. Toxicology of BV to the host 
brains was also evaluated by various analyses.  
3. In chapter 5, a novel method involving coating BV with cationic lipids – 
Lipofectamine 2000 and Cellfectin II to reduce its inactivation by the complement 
system, a major host response, was developed and tested in vitro.  
Findings from this investigation, for the first time, revealed the molecular level 
responses and the pathways activated in non-human primate brains upon BV 
inoculation and highlighted the differences in the response of mice and macaque to 
BV inoculation thus serving as a guide to rational therapeutic application of 
baculoviral vectors in the central nervous systems. Furthermore, the findings 
demonstrated the usefulness of a purification method in terms of immune responses 
and the suitability of cationic lipids in offering serum protective effect to BV. 
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2. Materials and Methods 
2.1. Cell lines 
Spodoptera frugiperda (Sf9) insect cells preadapted to Sf-900 II SFM (serum-
free medium) were purchased from Invitrogen (Carlsbad, CA) and grown in T175 
flasks at 27.5º C. Sf9 cells were passaged when ≈ 80-90% confluent and used for 
experiments. U87MG glioma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA) and maintained in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 
units/ml), and streptomycin (100 μg/ml). U87MG cells were passaged when ≈ 80% 
confluent and used for experiments within 20 passages from the time of initiation of 
the culture. 
2.2. Recombinant plasmids/baculoviral (BV) vector production 
pFastBac1 plasmid vectors containing the reporter genes encoding luciferase 
(luc) enzyme and enhanced green fluorescent protein (EGFP) under the control of 
cytomegalovirus (CMV) enhancer/promoter were constructed as described previously 
(Wang and Wang 2006). These vectors were used to produce recombinant 
baculovirus (rBV) accommodating luc and EGFP genes respectively in accordance 
with the Bac-to Bac baculovirus expression system (Invitrogen). P3 baculovirus 
containing herpes simplex virus thymidine kinase (HSVtk) therapeutic gene under the 
control of CMV enhancer-glial fibrillary acidic protein promoter (CMV E/GFAP), an 
engineered cell type specific promoter were constructed as described previously 
(Wang et al., 2006b, Wu et al., 2009). Sf9 cells were infected with various P3 rBV at 
an MOI of 0.05 at 50% confluence in 175-cm2 tissue culture flasks. Supernatants 
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containing rBVs were collected 72 hr post infection.  
2.3. Determination of infectious titer and total viral particles 
Infectious viral titres were determined by plaque assay. Sf9 cells were seeded 
in 6-well plates at 50% confluence. One ml of different dilutions (10-3 to 10-8) of 
baculovirus supernatants in Sf-900 II SFM was added to each well. After 1 hour of 
incubation at room temperature, medium containing virus was aspirated and 1% 
nutrient agarose was overlaid on to Sf9 cells. Plaques were counted after 7-10 days. 
Total viral particles were determined by quantitative real-time PCR (qRT-PCR) assay. 
Viral genomic DNA was isolated from 200 μl of budded virus using High Pure Viral 
Nucleic Acid kit (Roche Diagnostics, Penzberg, Germany) according to the 
manufacturer's protocol. qRT-PCR reactions to quantify baculovirus copy number 
was carried out in a final volume of 25 μl. Each reaction contained 12.5 μl of iQ 
supermix (Biorad, Hercules, CA), 100 nM of forward primer (5'- 
AAAGCAACCTCATAACCACCATG), 100 nM of reverse primer (5'- 
CCAATTCGCCTTCAGCCATG) and 100 nM of Taqman probe (6-FAM-5'-
CAGACTGGTGCCGACGCCGCC-BHQ1). DNA amplification was carried out using 
iCycler iQ™ Real Time PCR Detection system (Bio-rad) in triplicates with the 
following cycling conditions: 1) 95 °C for 3 minutes 2) 40X of 95 °C for 15 seconds 
and 60 °C for 1 minute. For each run, triplicates of five 10 fold dilutuions (103 to 108 
copies of gp64) of the viral standard DNA (pFastBac-CMV-gp64), viral DNA samples 
and non-template controls were subjected for analysis.  
2.4. Virus purification  
Budded viruses harvested from Sf9 cells were clarified by centrifugation at 
1000 g for 5 minutes and filtered through 0.45 μm filter to remove cell debris. rBVs 
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were then purified and concentrated by two methods- one involving a single step of 
high-speed centrifugation (HS) and the other comprising two steps – membrane 
chromatography for purification and high speed centrifugation for concentration 
(MC+HS).  
2.4.1. HS - High-speed centrifugation method 
Baculoviral supernatant was centrifuged at a high speed of 28000 g for 1 hour 
at 4º C in Avanti™ J-25 centrifuge (Beckman Coulter, Leeds, UK). The supernatant 
was aspirated out and the pellet was resuspended in appropriate volumes of 1X PBS 
with a salt concentration of 150 mM NaCl  and pH 7.4. The concentrated virus 
formulation was put on Stuart orbital shaker (Bibly Scienctific, Staffordshire, UK) for 
at least 1 hour for even dispersion. 
2.4.2. MC+HS - Membrane chromatography + high speed centrifugation 
method  
Acrodisc chromatography unit with a Mustang S cation exchange membrane 
(Pall Corporation, Port Washington, NY) was preconditioned with 5 ml of 0.2 N NaOH 
and equilibrated with 10 ml of 25 mM MES buffer (pH 6.0). Ten ml of viral 
supernatant either at room temperature or 4º C was passed through the membrane 
chromatography unit at a flow rate of 3 ml/min. The membrane was washed with 5 ml 
of equilibration buffer. Baculovirus was eluted first with 5 ml of PBS-150 mM NaCl 
and later with PBS-500 mM NaCl at pH 7.4. The combined eluate was subjected to 
high-speed centrifugation at conditions mentioned previously and the pellet was 
dissolved in appropriate volume of 1X PBS with a salt concentration of 150 mM NaCl  
at pH 7.4. The concentrated virus formulation was evenly dispersed by placing it on 
orbital shaker for at least 1 hour. 
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2.5. Protein gel electrophoresis, western blot and silver staining 
Western Blot for gp64, the major envelope glycoprotein of baculovirus, was 
performed to check for the presence of baculovirus in the purified formulation. Mock 
infected Sf9 cell cultured medium, baculovirus containing supernatant, flow-through, 
wash and collected elution fractions were mixed with 4X LDS sample buffer 
(Invitrogen) and 10X sample reducing agent (Invitrogen) and heated at 70º C for 10 
minutes for denaturing the proteins. Samples (40 μl) and SeeBlue® Pre-Stained 
Standard (Invitrogen) were loaded on to precast 4-12% NuPAGE Novex Bis-Tris 
polyacrylamide gels (Invitrogen) and electrophoresed in MES running buffer for 2 
hours at 80 V.  Following electrophoresis, separated proteins on the gel were 
transferred onto a nitrocellulose membrane using the iBlot transfer stack on an iBlot 
dry blotting system (Invitrogen) following the manufacturer’s instructions. Complete 
transfer of protein was assessed by the visible transfer of ladder proteins. 
Membranes were blocked in blocking solution [5% (w/v) non fat dry milk, 0.1% (v/v) 
TritonX-100 in PBS] for 1 hr at room temperature. After blocking, membranes were 
incubated with baculoviral gp64 antibody (sc-65499, Santacruz Biotechnology, Santa 
Cruz, CA) raised in mouse (dilution - 1:1000) in blocking solution, overnight at 4 °C 
on an orbital shaker. After incubation with primary antibody, membranes were 
washed 3 times for 10 mins each on an orbital shaker in PBST [0.1% (v/v) TritonX-
100 in PBS] at room temperature. Membranes were then incubated with the 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody, diluted in 
PBST, for 1 hr at room temperature. After incubation, membranes were washed 3 
times for 10 mins each in PBST with shaking. Visualization of bound antibody was 
done using ECL Plus western blotting detection reagent (GE Healthcare, Amersham 
Place, Little Chalfont, Buckinghamshire). Resulting chemiluminescent signal was 
 
43 
detected with CL-XPosure Film (Thermo Scientific, Rockford, IL). Exposed films were 
imaged on FluorChem HD Gel Doc System using white light transillumination (Alpha 
Innotech, Santa Clara, CA).  
Silver staining was used to analyse the purity of the virus formulation. SDS-
PAGE for various virus samples was carried out as described earlier and the gels 
were stained with silver iodide solution in accordance with the Silver Quest Silver 
staining kit protocol (Invitrogen). Stained gels were imaged on FluorChem HD Gel 
Doc System using white light transillumination (Alpha Innotech).  
2.6. Determination of transduction efficiency 
The transduction efficacy was determined on the basis of baculoviral 
transduction of human U87MG cells with BV-luc and BV-EGFP. Cells were seeded at 
the count of 10000/well in 96-well plates and after attachment, equal number of BV-
luc viruses corresponding to MOI 50 from various samples were used in transduction 
in serum free medium. After incubation at 37 ºC for 4 hours, the medium containing 
viruses was replaced with 10% FBS containing fresh growth medium. After 36-48 
hours, when luciferase gene expression stablised, the cells were lysed by freeze-
thaw in Reporter Cell Lysis Buffer (Promega, Madison, WI) and luciferase activities 
were measured with a Berthold Lumat LB detecting 9507 luminometer (Berthold 
Detection Systems, Pforzheim, Germany). Protein concentrations were quantified 
using DC protein assay kit (Bio-Rad). For quantification, 5 μl of protein lysates were 
mixed with 25 μl working Reagent A and 200 μl Reagent B in a 96-well plate and 
incubated for 15 mins at room temperature. Absorbance was measured at 750 nm in 
a microplate reader (Bio-Rad). Concentration of protein lysates was obtained from a 
standard curve produced with dilutions of bovine serum albumin solution (BSA) 
 
44 
prepared in Reporter Cell Lysis Buffer (Promega), ranging from 0.125 - 2 mg/ml 
protein concentration. 
For measuring transduction efficiency of BV-EGFP, cells were seeded at a 
density of 2x106 per well in 6-well plates and imaged after 36-48 hours using 
fluorescence microscopy (Olympus). Percentage of EGFP positive cells was 
determined by flow cytometry using FACSCalibur (BD Biosciences). Cells from each 
well were trypsinized, washed with PBS twice and resuspended in 1 ml of PBS 
containing 5% FBS and transferred to appropriate tubes (5 ml polystyrene tubes from 
BD Falcon) for flow cytometry analysis. Fluoresecent measurements were taken on 
the FL-2 channel for at least 10, 000 events gated for EGFP positive cells. 
2.7. In vivo studies 
2.7.1. Virus inoculation into mouse brains 
For in vivo viral vector inoculation into mouse brains, three adult male 
immunocompetent BalB/c mice were used for each group of Mock-, MC+HS- and 
HS- purified BV injections. 10 μl of BV-HSVtk (108 viral particles) was injected 
stereotaxically into each side of the striatum of the mouse brain (anteroposterior: 0.0 
mm, mediolateral: +2.0 mm, and dorsoventral: −3.0 mm from bregma and dura) 
using a 10 μl Hamilton syringe connected with a 30G needle. Brain samples around 
the injection sites were collected 2 days (≈ 48 hours) after virus inoculation and 
stored in RNA Later (Ambion, Austin, TX) at 4 ºC until used for RNA extraction. 
Studies on mice were performed following the Guidelines on the Care and Use of 
Animals for Scientific Purposes issued by National Advisory Committee for 
Laboratory Animal Research, Singapore. The experimental protocols of the current 
study were approved by the Institutional Animal Care and Use Committee (IACUC), 
 
45 
National University of Singapore (NUS) and Biological Research Centre (BRC), the 
Agency for Science, Technology and Research (A*STAR), Singapore.  
2.7.2. Virus inoculation into macaque brains 
For studying the host response and toxicology to recombinant baculovirus in 
non-human primates, 3 adult male cynomolgous macaques (Macaca fascicularis) 
weighing approximately 3-4 kg were used. BV-HSVtk (108 viral particles in 10 μl per 
injection site) purified by MC+HS was administered as 4 separate intrastriatal 
microinjections into the left hemisphere (anteroposterior: 0.0. mm and +3.0. mm to 
the bi-lateral commissural line targeting the centre of caudate and putamen) (Figure 
2.1). The right hemisphere was injected with mock virus preparation. Mock virus 
preparation refers to Sf9 culture medium containing no baculovirus subjected to 
purification by MC+HS method.  Brain samples were collected approximately after 2 
days (≈ 48 hours) of virus inoculation and stored in RNA Later at 4º C unti further use 
in RNA extraction. Real time PCR for gp64 was used to verify the successful injection 
of BV-HSVtk into the animal brains. Samples for real-time PCR were collected in dry 
tubes and stored at -80 ºC until further use in genomic DNA extraction. Studies on 
macaques was performed following the IACUC protocol of Maccine Pte Ltd and to 




Figure 2.1. Virus inoculation into macaque brains. (A) BV-tk purified by MC+HS 
was administered as 4 separate intrastriatal microinjections into the left hemisphere 
and mock into the right at sites marked on the skull (B) shows the injection sites after 
collecting brain 48 hours from the time of injection (C) shows the slicing procedure 
and (D) shows the sampling of injected sites from sliced brain samples. 
2.8. Sample preparation for cDNA microarray analysis 
2.8.1. Total RNA isolation 
Total RNA comprising all RNAs including mRNAs, rRNAs and small RNAs 
was isolated using Trizol (Invitrogen) reagent according to the manufacturer’s 
instructions. Precisely, tissues up to 100 mg were lysed and homogenized in 1 ml of 
Trizol reagent using Vibra-cell sonicator (Sonics & Materials, Newtown, CT). 
Following lysis, all samples were processed for phase separation after adding the 
recommended amounts of chloroform. RNA in the aqueous phase was carefully 
removed and precipitated using appropriate amounts of 100% ethanol. The gel-like 
RNA pellet was washed with 75% ethanol, dried thoroughly for ≈ 10 minutes to 
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remove as much ethanol as possible and resuspended in 50 μl RNAse free water. 
The amount and purity of isolated RNA samples were determined by measuring 
absorbance at 230 nm (A230), 260 nm (A260), 280 nm (A280) with a NanoDrop ND-
1000 Spectrophotometer (Thermo Scientific, Waltham, MA). An A260/A280 ratio of 
1.8-2.0 and A230/A260 ratio of 1.9-2.2 indicated RNA free of contaminants and was 
used for subsequent procedures. RNA was stored at -80 °C until use and freeze-
thawing was limited to less than 5 times.  
2.8.2. RNA clean up 
Total RNA was cleaned up to remove RNAs < 200 nucleotides (usually 5.8S 
rRNA, 5S rRNA, and tRNAs) and enriched for mRNAs using RNeasy mini kit 
(Qiagen, Hilden, Germany). Precisely, total RNA isolated by Trizol method was made 
up to 100 μl and mixed with 350 μl of buffer RLT and 250 μl of 100% ethanol to 
constitute 35% v/v ethanol in the mixture. The mixture was loaded on to the RNeasy 
spin column. At this concentration of ethanol, the RNeasy spin column binds only 
RNA > 200 nucleotides (otherwise only mRNAs). The bound mRNAs were washed 
twice with Buffer RPE and eluted using 30-50 μl RNase free water. Cleaned up RNA 
was again quantified using a NanoDrop ND-1000 spectrophotometer.  
2.8.3. RNA amplification and labeling 
RNA amplification and labeling was done using Kreatech’s RNA ampULSe 
amplification and labeling kit (Kreatech, Amsterdam, The Netherlands). Starting with 
one μg of good quality RNA (i.e. A260/A280 > 2.0 and A230/A260 > 2.1) in 10 μl, first 
strand cDNA was synthesized using T7 oligo dT primer following the instruction 
manual. The reaction mixture for first strand cDNA synthesis additionally contained 
diluted eukaryotic poly(A) RNA controls (Affymetrix) as recommended by Affymetrix 
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protocol to serve as controls for all steps of sample preparation and array 
hybridization. The end product of first strand cDNA synthesis was entirely used for 
second strand cDNA synthesis using DNA polymerase and purified according to the 
instruction manual. Double stranded cDNA obtained at the end of this process was 
used as a template in a 4 hour in vitro transcription process performed at 37 ºC for 
synthesizing amplified RNA (aRNA). aRNA was purified using columns provided in 
the kit. The yield and purity of aRNA was determined using NanoDrop. Thirty μg of 
aRNA was labeled with 5 μl biotin-coupled ULS for 30 mins at 85 °C. Following this, 
unincorporated biotin-ULS was removed using KREApure bead columns as 
recommended. Purified labeled RNA (20 μg) was then fragmented using RNA 
fragmentation reagent (Ambion, Foster city, CA) following the manufacturer’s 
instructions. 
2.8.4. Hybridisation, washing and scanning 
A hybridisation mix of total volume 300 μl was prepared as follows: 
Component Volume (μl) Source 
Fragmented and Labeled aRNA 30 Product of amplification and labeling (Kreatech) 
Control Oligonucleotide B2 (3nM) 5 Affymetrix 
20X Eukaryotic Hybridization 
Controls 15 Affymetrix 
2X Hybridization mix 150 Affymetrix 
Krea Bloc 75 Kreatech 
Nuclease free water 25 Promega 
For mouse brain samples, GeneChip Mouse Genome 430A 2.0 Array and for 
macaque brain samples, GeneChip Rhesus Macaque Genome Array were used. The 
arrays were pre-hybridized with 200 μl Prehybridization mix (Affymetrix) for 10 mins 
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at 45 °C with rotation. Meanwhile, the hybridization mix was heated to 99°C and 
centrifuged to pellet insoluble materials, as recommended by Affymetrix hybridization 
protocol. Finally, 200 μl of each hybridization mix was hybridized to a GeneChip 
array for 16 hours at 45 ºC. Array washing and staining was done on the GeneChip 
Fluidics Station 450 (Affymetrix) following the recommended protocol. For washing 
and staining, the fluidics protocol FS450_0004 was used. Scanning of arrays was 
done on the GeneChip Scanner 3000. Array quality was determined from the signal 
intensities of internal control and the percentage of absent and present calls made by 
the GeneChip Operating Software for each array. 
2.9. Data analysis  
2.9.1. By Genespring GX 11 
Data from the chips were acquired using the GCOS software and all data files 
were exported using the Data Transfer Tool (DTT). Data files in .CHP format were 
transferred to GeneSpring GX 11 (Agilent) software. The files were normalized using 
the default setting of the software i.e to the median of percentile target (75.0) of all 
samples and were applied a baseline transformation to median of all samples. 
Replicates (at least 3 per group) were grouped together based on treatment (virus 
injected/mock injected) and the probes in the normalized data were subjected to 
quality control based on expression and flags. Probes with either present or marginal 
flags in at least 2/3 of the samples in both control and experimental samples were 
then filtered such that there is a fold change of at least 2 in experimental samples 
pooled together against the control samples pooled together and then subjected to 
statistical analysis by t-test with a p-value of 0.05.  
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2.9.2. Genelists analysis by web-based services 
To understand the biological meaning of the list of genes significantly 
modified by baculovirus injection against the mock injection in brain samples, 
Metacore™ (GeneGo) and Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7 Bioinformatics Resources (Huang et al., 2008a) 
(http://david.abcc.ncifcrf.gov/) were used. The list of both upregulated and 
downregulated genes were analysed together in Metacore or DAVID using their 
default settings for obtaining the Gene Ontology (GO) processes and pathways 
affected.  
2.10. Quantitative real time-PCR of mRNAs  
A portion of the total RNA isolated was used for the validation of microarray 
data using quantitative Real Time-PCR.    
2.10.1. DNAse treatment of RNA samples 
Total RNA was DNAse-treated to remove traces of genomic DNA 
contamination that would contribute to subsequent PCR amplification product. 
Typically, two μg of total RNA was treated with 1 μl (2 units) of Turbo DNAse 
(Ambion) in 20 μl volume for 30 min at 37 °C, followed by addition of another 1 μl of 
Turbo DNAse to the sample for further 30 minutes incubation at 37 °C. At the end of 
the incubation, 4 μl (0.2 volumes of 20 μl) of DNAse inactivation reagent was added 
to the sample and incubated at 25 °C for 5 minutes, with repeated dispersal of the 
inactivation reagent every minute by flicking the tube. For removal of DNAse 
inactivation reagent, tubes were centrifuged at 10,000 x g for 1.5 mins and ≈ 15 μl of 
DNAse treated sample was carefully removed without disturbing the inactivation 
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reagent pellet, and transferred to a fresh tube.  
First strand cDNA was synthesized from 1 μg of DNAse-treated total RNA 
using Superscript III reverse transcriptase (Invitrogen). cDNA was diluted 10-fold 
before amplification in a 25 μl reaction with iQ5 SYBR-Green PCR Mix (Biorad). Each 
reaction consisted of 2 μl diluted cDNA, 1 μl (2.5 μM) of the RT2 qPCR Primers 
corresponding to each gene (SABiosciences, Fredrick, MD), 9.5 μl nuclease-free 
water and 12.5 μl PCR mix. The cycling conditions included an initial denaturation 
step of 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95 °C and 30 
seconds at 60 °C. All reactions were done in triplicates on Bio-Rad iCycler. 
Expression levels were normalized to mouse and rhesus glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)  for mouse and macaque mRNA samples 
respectively. For each primer pair, negative control PCR reaction with nuclease-free 
water was performed in duplicates. Relative gene expression level was obtained by 
triplicate experiments from each of the mouse brain samples and at least two of the 
monkey brain samples. The fold changes between the experimental and control 
samples were calculated according to instructions in the manual. 
2.11. Preparation of cationic lipids coated BV  
rBV coding for luciferase enzyme (BV-luc) were coated with either of the two 
cationic lipids - Lipofectamine 2000 and Cellfectin II (both from Invitrogen). 
Lipofectamine 2000 is an advanced version of Lipofectamine, a 3:1 (w/w) liposome 
formulation of the polycationic lipid 2,3-dioleyloxy -N- [2(sperminecarboxamido)ethyl]-
N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid 
dioleoyl phosphatidylethanolamine (DOPE) in membrane-filtered water majorly used 
in the transfection of DNA into cultured eukaryotic cells. Cellfectin II reagent is the 
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improved Cellfectin, a 1:1.5 (M/M) liposome formulation of the cationic lipid N, NI, NII, 
NIII-Tetramethyl- N, NI, NII, NIII-tetrapalmityl-spermine (TM-TPS), and dioleoyl 
phosphatidylethanolamine (DOPE) in membrane-filtered water used in the 
transfection of DNA into insect and mammalian cells especially Sf9 insect cells. Both 
cationic lipids are available in stock solutions of 1mg/ml. For coating, the cationic 
lipids were diluted in PBS to the required concentrations (104 - 107 molecules/particle 
BV), mixed with BV-luc concentrated by HS method and incubated at room 
temperature for 20-30 minutes.  
2.12. Size and zeta potential characterization of uncoated and cationic-
lipid coated BV 
Uncoated and cationic lipid coated BV-luc in distilled water were 
characterized for their size by dynamic light scattering (DLS) and zeta potential by 
electrophoresis using Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK). 
Precisely, 750 μl of the uncoated or coated BV-luc were loaded into folded capillary 
cell using 1 ml syringe. Care was taken to see that no air bubbles were introduced 
while loading. A minimum of 5x109 particles/per sample was used for size and zeta 
potential measurements. Data were exported in .csv format to excel and graphs were 
plotted using Graphpad Prism 5. 
2.13. Cytotoxicity assay 
Cytotoxicity of cationic lipid coated BV was assessed using CellTiter 96 
AQueous One Solution Cell Proliferation Assay System (MTS) (Promega) on U87MG 
glioma cells as a representative mammalian cell line. U87 cells were seeded in 96 
well plates at a confluency of 50% and allowed to attach overnight. Uncoated and 
coated BV (104 - 107 molecules/BV particle) at an MOI (multiplicity of infection) of 10, 
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50, 100 and 500 were added to the cells in serum free and antibiotic free medium. 
After 4 hours of incubation, medium containing uncoated and coated BV were 
removed and cells were replenished with serum containing medium. After 48 hours of 
incubation, 40 μl of the MTS reagent (20 μl MTS solution/100 μl of medium) was 
added directly to the medium, incubated at 37º C for 2-3 hours and absorbance was 
measured at 490 nm in a microplate reader (Bio-rad). 
2.14. Transmission electron microscopy (TEM) 
Changes in the morphology of uncoated/ coated baculovirus when treated 
with serum complement were observed using transmission electron microscopy 
(TEM). Baculovirus (uncoated/coated and serum treated/noserum treated) samples 
were prepared in deionised water. 4 μl of the various samples were placed on 
Formvar/Carbon coated Copper 200 mesh (Polysciences, Warrington, PA) for a 
minute and the remaining solution was wiped off using a filter paper. The grid was 
washed with 4 μl deionized water  once for 1 minute and the sample was stained with 
4 μl of 2% phosphotungstic acid (PTA). Excess stain was washed away using 
deionized water. The grid was air dried for a few minutes and imaged under a 200kV 
TEM (FEI, Hillsboro, OR). 
2.15. Complement assays and in vitro transduction studies 
The protective effect of cationic lipid coating on BV-luc against serum 
complement system was tested in vitro using mouse, rat and human serum 
complement. Balb/C mouse and Wistar rat serum complement were obtained from 
Innovative Research (Sarasota, FL). Lyophilized powders of human serum (S-1764) 
were obtained from Sigma Aldrich (St. Louis, MO) and reconstituted in 1 ml of sterile 
deionised water. For inactivation treatment, mouse, rat or human serum complement 
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were mixed with coated/uncoated baculoviruses in the ratio of 1:1 (volume not 
exceeding 5% of the medium in a 96 well plate) for 30 minutes at 37 ºC. Transduction 
efficacy of serum treated, uncoated and coated BV-luc were tested on U87 glioma 
cells as described earlier and compared against no serum treated uncoated/coated 
BV as positive controls. 
 
55 
3. Purification of BV by Membrane Chromatography Method 
Reduces Immune Responses in Mouse Brains 
3.1. Introduction and Aims  
With growing applications of baculovirus (BV) in various fields including 
pesticide development, recombinant protein production and gene therapy vectors, 
several circumstances require the use of concentrated and purified BV. For instance, 
large scale protein production in insect cells require highly concentrated and pure BV 
inoculum. In vivo gene therapy applications require a high titre of BV in a small 
volume of physiological buffer.  BVs being insect viruses and are propagated in 
insect cells, the chances of contamination of recombinant BV (rBV) formulation with 
insect cell DNA and proteins are high. Insect cells infected with rBV expressing MHC 
peptide complexes have been shown to be recognised, processed and presented by 
host antigen presenting dendritic cells (DCs) which further generate functional 
antigen specific CD8+ T cell responses (Jordan et al., 2008). This highlights the 
contribution of insect cells and proteins to the immune responses of the host and 
underscores the necessity to remove the unwanted insect cell contaminants when 
rBV are used as gene therapy vectors for in vivo studies.  
Several different methods have been developed so far for purifying rBV. Each 
method has its own pros and cons. For example, immobilized metal affinity 
chromatography improved the purity of BV up to 87% but compromised the final 
recovery yield which was only 2-3% (Hu et al., 2003). Size exclusion chromatography 
resulted in recovery of 25% of total virus particles but the purity was compromised as 
judged by the SDS-PAGE results (Transfiguracion et al., 2007). While 
concanavalin A affinity chromatography resulted in 29.3% overall recovery (Chen et 
al., 2009b), a multistep downstream processing involving anion exchange 
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chromatography resulted in  an overall recovery of 38% (Vicente et al., 2009). 
Making use of the easy scalability and faster processing times associated with 
membrane chromatography (Zuo et al., 1999), previous studies in our laboratory 
demonstrated cation exchange membrane chromatography to provide good purity 
and 78.1% recovery of rBV (Wu et al., 2007). However, none of these studies 
demonstrated the biosafety associated with the material purified from these methods 
in vivo, particularly, in terms of immune responses in the host upon delivery of rBV 
prepared by various methods. With DNA microarrays becoming increasingly popular 
to monitor host responses to virus and virus-derived gene therapy vectors (Piersanti 
et al., 2004), the task of evaluating molecular impact by different formulations on the 
host is much easier. Therefore, this chapter  aims to improvise the existing cation 
exchange membrane chromatography purification protocol (Wu et al., 2007) in order 
to substantially improve the purity of BV to generate in vivo grade formulation and 
demonstrate the biosafety associated with this method in vivo in mouse brains using 
global gene expression profiling.  
3.2. Recovery of rBV from cation exchange membrane chromatography 
unit 
The cation exchange membrane chromatography unit preconditioned with 
0.2 N NaOH was equilibrated with 25 mM MES buffer, the working pH range of which 
accommodates rBV-supernatant of pH ~6. Virus supernatant at room temperature 
was passed through the membrane chromatography unit and the flow through (FT) 
was collected. The chromatographic unit was washed with MES buffer of same pH to 
remove unbound proteins and viruses. PBS of pH 7.4 with NaCl of concentrations -
150 mM and 500 mM were used to elute the virus. Real-time PCR assay for gp64 
was performed on rBV supernatant, FT, wash and eluates to calculate the 
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percentage recovery.  Most of the viruses bound to the membrane as evidenced from 
lesser percentage of viral particles in FT and wash (Table 3.1), thus indicating a 
strong interaction between viruses and the membrane. The first two eluates (E1-150 
and E2-150) in PBS-150 mM NaCl contained 25% and the first two eluates (E1-500 
and E2-500) in PBS-500 mM NaCl contained 47% of the viral particles. Totally, 72% 
of the viral particles were recovered in 2 ml of the eluate (Table 3.1). Recovery could 
be further improved to ≈ 90% by applying more elution buffer. A representative data 
set presenting recovery by real-time PCR and plaque assay is provided in Table 3.1. 
However, the recovery was not always as high as 90% and drastically varied 
with the temperature of the rBV-supernatant passed through the membrane 
chromatography unit. When cold (≈ 4 ºC) rBV-supernatant was passed through the 
acrodisc unit, most of the viral particles bound to the unit as evidenced by the lesser 
percentage of rBV particles in FT (Figure 3.1). But, only ≈ 40% of virus particles were 
recovered in the eluate suggesting too strong an interaction between viruses and the 
membrane making it difficult for the elution buffer to break it. These data underscored 
the importance of temperature of rBV-supernatant in obtaining high recovery. 
 Sample Volume (ml) 
Real Time PCR Plaque assay 
VP/ml Total VP1 % recovery2 PFU/ml Total PFU1 % recovery2 
BV Load 10 1.60E+09 1.60E+10  5.20E+07 5.20E+08 !Flow through (FT) 10 1.19E+08 1.19E+09 7.43 - - !Wash 5 2.23E+07 1.11E+08 0.70 - - !
! ! ! ! ! ! ! !E1-150 0.5 5.58E+09 2.79E+09 17.40 - - !E2-150 0.5 2.30E+09 1.15E+09 7.17 - - !E1-500 0.5 1.09E+10 5.47E+09 34.16 - - !E2-500 0.5 4.21E+09 2.10E+09 13.12 - - !
E1-150+E2-150 
+E1-500+E2-500 2  1.15E+10 71.86 - - !
       !Total Eluate  10 1.44E+09 1.44E+10 90.12 4.49E+07 4.49E+08 86.35 
Table 3.1. Recovery of recombinant baculoviruses after purification by membrane chromatography.VP - viral particles; PFU – plaque 
forming units; 1-Total viral particles (TVP) and Total PFU was calculated by multiplying viral particles and PFU respectively with volume; 2 - 
Recoveries were calculated by normalizing the data against the loaded sample;  E1, E2 – First and second elute; 150, 500 – Concentration of 






Figure 3.1. Effect of temperature of rBV-supernatant on recovery from 
membrane chromatography method. rBV-supernatant at 4 ºC and room 
temperature (RT) were passed through the membrane chromatography unit and 
eluted using PBS-150 mM and 500 mM NaCl. Using real-time PCR for gp64, the 
major BV envelope glycoprotein, number of rBV particles in eluate and flow through 
were measured and expressed as % recovery by normalizing against those in loaded 
samples.  
3.3. Transduction efficiency of recovered rBV 
To test the transducing ability of rBV purified by membrane chromatography 
method, rBV encoding reporter genes – luciferase and enhanced green fluorescent 
protein (EGFP) were used.  rBV eluates were collected in fractions and 5 μl of each 
fraction was used for analysing the transduction efficiency on U87 cells in a 96 well 
plate. Reporter gene expression was analyzed after 48 hours of transduction. BV-luc 
eluted with PBS-150 mM NaCl, (E1-150 and E2-150) showed higher luciferase 
expression (Figure 3.2A) than non-concentrated load sample. This could be 
attributed to the increased number of viral particles in the eluates. Further fractions 
collected using PBS-150 mM NaCl did not show better luciferase expression than 
that used to load the chromatographic unit (data not shown) which might be because 


















Figure 3.2. Transduction efficiency of rBV expressing reporter genes purifed 
by cation exchange membrane chromatography. Luciferase (A) and EGFP (B) 
gene expression for various virus fractions were measured after 48 hours on U87 
cells transduced with BV-luc and BV-EGFP respectively. FT-Flow through; E1, E2 – 

















































Similar trend was observed with fractions eluted using PBS-500 mM NaCl. Precisely, 
first two eluates (E1-500 and E2-500) displayed higher luciferase expression than 
load sample whereas the eluates obtained later showed lesser luciferase expression. 
Consistent with the number of viral particles recovered, U87 cells transduced with 
E1-500 and E2-500 expressed more luciferase than E1-150 and E2-150.  
The same set of experiments were performed with rBV encoding enhanced 
green fluorescent protein (EGFP) encoding gene and similar expression patterns 
were observed under fluorescence microscope (Figure 3.2B).  
3.4. Analysis of purity for recovered rBV 
To examine the purity of the virus samples eluted from membrane 
chromatography unit, eluted virus fractions together with mock supernatant (Sf9 
cultured supernatant not infected with BV), rBV load, FT and wash were denatured 
by boiling in 1% SDS sample buffer and proteins were resolved on SDS-PAGE and 
viewed using silver iodide staining (Figure 3.3A). As expected, virus supernatant 
contained an enormous amount of contaminating proteins. Comparison with the 
proteins in the lane of mock supernatant indicated that most of the proteins in BV-
load were of insect cell origin thus, emphasizing the need to remove them for 
minimizing the immune responses to rBV as a gene therapy vector. Minimal amounts 
of gp64 and large amounts of other contaminating proteins could be spotted on FT 
lane. This indicated the strong interaction between rBV and the cation exchange 
membrane at pH 6. Relatively lesser contaminating proteins and trace amounts of 
gp64 were present in wash thus proving helpful in washing away some of the 
contaminating proteins. Far lesser contaminating proteins and enrichment for gp64 
characterized the lanes containing eluates. This indicated the successful elution of 
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rBV at pH 7.4. Abundant proteins studded on the lane – proteins on the membrane 
indicated the retainment of humongous amounts of proteins on the membrane even 
after elution of ≈ 90% of the rBV particles thus indicating the selectivity of pH to elute 
only rBV from the membrane. A western blot analysis for gp64 performed on various 
samples reconfirmed the presence of rBV. The results were in agreement with the 
findings from real-time PCR and SDS-PAGE (Figure 3.3B). Thus, these results 
provide evidences for the usefulness of membrane chromatography method in 
purifying BV without considerable loss in recovery and transduction efficiency. 
3.5. Concentration of rBV 
Though purification by membrane chromatography method offered better 
purity, in an attempt to maximize the elution to ~90% by increasing the volume of 
elution buffer, the concentration was compromised. To concentrate BV, a second 
step involving centrifugation of the eluate fractions at a high speed of 28,000 g at 
4 ºC for one hour was included. The pellet was dissolved in appropriate amounts of 
PBS (pH 7.4) containing 150 mM NaCl. To examine if the two step purification 
process affected virus quality, the prepared formulation was tested for recovery, 
transduction efficiency and purity and compared against virus formulation purified by 
the commonly used laboratory method involving only high speed centrifugation (HS) 




Figure 3.3. Analysis of rBV formulation before and after purification by 
membrane chromatography. Various virus fractions were electrophoresed on 
sodium dodecyl sulphate-polyacrylamide gels and total proteins were viewed using 
silver iodide staining (A) and gp64 viewed by western blot (B). denotes gp64. Note 
the lesser amount of total proteins in eluates indicated by fewer and lighter protein 
bands compared to BV-load and abundant amounts of total proteins in the last lane 




































































































3.6. Comparison of rBV purification methods for recovery, transduction 
efficiency and purity  
Purification by high-speed centrifugation (HS) method yielded a final recovery 
of ~55% by real time PCR assay for gp64 and the two-step purification process 
(MC+HS) yielded a final recovery of 29% ± 5 (represented as Mean ± SD of three 
independent sets of purification). Since the high speed centrifugation method of 
purifying baculovirus is always associated with a loss of ~50%, it was not surprising 
that the recovery by MC+HS dropped to ~30%. A representative run of BV 





VP/ml Total VP1 
% 
recovery2 
BV-luc  10 6.08E+09 6.08E+10  
HS HS 0.3 1.12E+11 3.35E+10 55 
MC+HS 
Step1 
E-150 5 8.08E+09 4.04E+10 66 
E-500 5 2.71E+09 1.35E+10 22 
Step 2 MC+HS 0.5 3.91E+10 1.95E+10 32 
Table 3.2. Summary of total BV yield and final recovery after purification by 
High Speed Centrifugation and Membrane Chromatography+high speed 
centrifugation. VP- viral particles; 1-Total viral particles (TVP) was calculated by 
multiplying viral particles with volume; 2 - Recoveries were calculated by normalizing 
the data against the loaded BV-luc sample E-150- BV eluted with PBS-150mM NaCl 
at pH 7.4; E-500- BV eluted with PBS-500mM NaCl at pH 7.4. 
The reverse of this process, that is, purification of baculovirus by 
centrifugation at high speed followed by membrane chromatography was also tried 
(data not shown). However, when membrane chromatography was used as the 
second step, virus could not be efficiently eluted using a smaller volume of elution 
buffer and the concentration was compromised when trying to maximize the recovery 
yield. To check the effect of purification procedures on the transduction efficiency, 
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equal number (MOI 50) of purified BV-luc from both methods and BV-luc supernatant 
were tested for their transduction activity. Transduction by MC+HS-purified BV-luc 
resulted in transgene expression comparable to that resulted from transduction by 
HS-purified BV. Though there were slight differences in luciferase gene expression 
between transduction by MC+HS purified and HS-purified BV, the variations were not 
statistically significant. (Figure 3.4A). The purity of the samples were assessed by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed 
by silver staining. As shown in Figure 3.4B, BV-luc supernatant collected from Sf9 
cell cultures, clarified by centrifugation at 1000 g for 5 minutes and filtered through 
0.45 μm pore sized filter contained abundant proteins. MC+HS purified virus 
formulation displayed a single major band of molecular mass ≈ 64 kDa correlating to 
gp64 whereas HS purified virus formulation displayed a major band of gp64 together 
with other protein bands indicating the presence of contaminating proteins. The 
presence of BV in various formulations were confirmed by western blot for gp64 
(Figure 3.4C). These results suggested that MC+HS purification method offered 




Figure 3.4. Transduction efficiency and purity of BV-luc purified by membrane 
chromatography + high speed centrifugation (MC+HS) method and high speed 
centrifugation (HS) method alone. (A) Comparison of transduction efficiency of BV-
luc before and after purification by the two methods. Luciferase activities were 
measured after 24 and 48 hours. Each group consisted of at least three repeats and 
values are expressed as mean + SD. Note that there is no significant differences in 
luciferase expression (B) Purity of virus preparations before and after MC+HS and 
HS purification by silver staining. Note that MC+HS lane has a single band of 
proteins corresponding to molecular weight of ≈ 64 kDa as against multiple protein 
bands in other lanes. denotes gp64. (C) Confirmation of the presence of BV in 













































3.7. Comparison of rBV purification methods for immune responses in 
mice brains by cDNA microarray analysis 
3.7.1. rBV formulations prepared by MC+HS and HS methods considerably 
alters gene expression in mice brains 
To verify the usefulness of MC+HS method in adding to the biosafety profile 
of BV for treating CNS disorders, microarray analysis on mice brain striatum 
inoculated with MC+HS-purified rBV was performed and compared with those 
inoculated with HS-purified rBV using Affymetrix GeneChip Mouse Genome 430 2.0 
Array. rBV accommodating HSVtk gene under the control of GFAP promoter and 
appended to three repeats of three micro RNA sequences (hsa-miR-31, hsa-miR-127 
and hsa-miR-143) shortly referred to as BV-tk that were used to treat gliomas in mice 
models (Wu et al., 2009) were used for this purpose. The chip offers a 
comprehensive analysis of genome wide expression on a single array comprising of 
45,000 probe sets for over 39,000 well characterized mouse genes. At least three 
mice brain samples from separate animals, each injected with mock, MC+HS-purified 
and HS-purified viruses were collected for microarray analysis. We observed 
approximately 61.3%, 59.37% and 60.1% of gene probes on the chip being flagged 
as present in MC+HS-purified BV-, HS purified BV- and mock - injected mouse brain 
samples respectively. GenespringGX 11.5 from Agilent Technologies was used for 
microarray data analysis. Using a two fold difference in normalized expression level 
and a t-test p-value of ≤ 0.05 as an arbitrary cut off value against the mock injected 
brain samples, we observed 379 probes (0.84%) in MC+HS purified BV injected 
brain samples and 431 probes (0.94%) in HS purified BV injected brain samples to 
be altered. The set of 379 gene probes from MC+HS purified BV injected brain 
samples represented 351 up regulated and 28 down regulated probes with a total of 
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378 IDs available in Database for Annotation, Visualization and Integrated Discovery 
(DAVID) bioinformatics resources 6.7 and the set of 431 gene probes from HS 
purified BV injected brain samples represented 406 up regulated and 25 down 
regulated probes with a total of 429 IDs available in DAVID. This is summarized in 
Table 3.3. These data indicate that rBV formulations prepared by both purification 
methods bring about alterations in considerable number of genes. 
 HS  MC+HS  








430 2.0 Array 
Total No. of Transcripts 
present 45101 45101 
Total No. of transcripts 
examined (present/marginal) 27438 27004 
Probes modified (2 fold 
change+p<0.05) 431 379 
Probes Up regulated 406 351 
Probes Down regulated 25 28 
% of modified genes 0.94 0.84 
Table 3.3. Summary of microarray data analysis on mice brains inoculated with 
HS and MC+HS purified BV by Genespring GX11. 
3.7.2. Validation of microarray results by real-time PCR assay 
To validate the fold changes in expression from microarray analysis, 8 
significantly modified (fold changes >= 2 and t-test p-value <= 0.05) genes 
participating in important KEGG pathways were analyzed by real-time PCR assay. 
The various KEGG pathways and the genes tested are as follows: 
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RIG-1 like receptor signaling pathway - MDA5, Isg15 and Irf7  
Antigen presentation and processing - Tap1 and Tapbp  
Chemokine signaling pathway - RANTES, CXCL11 and CXCL12  
Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
an internal normalization control. All of the selected genes displayed similar trend in 
up or down regulation consistent with those from the microarray analysis even 
though the actual fold changes were not identical (Figure 3.5). Due to the intrinsic 
differences in the techniques used and normalization methodology, absolute values 
could be different between the results obtained with microarray and real-time PCR 
assay. For example, it is likely that pixel saturation occurs when the pixel intensity 
exceeds a threshold in a microarray, thus compressing the true induction magnitude 




Figure 3.5. Validation of fold changes in expression by microarray results 
using quantitative real time PCR assay for mouse genes. Eight (seven 
upregulated – MDA5, Isg15, Irf7, Tap1, Tapbp, RANTES, Cxcl11 and one 
downregulated - Cxcl12) of the significantly modified (fold changes >= 2 and t-test p-
value <= 0.05) genes from MC+HS (A) and HS (B) purified BV-tk injected mouse 
brain samples were analyzed. Glyceraldehyde-3-phosphate dehydrogenase 





































































3.7.3. Molecular responses in mice brains to MC+HS- and HS-purified BV  
Molecular responses to rBV in mouse brains were analyzed using three 
different softwares – Genespring GX11.5, Metacore™ and DAVID Bioinformatics to 
gain insight into different issues. To obtain the list of genes differentially expressed 
between MC+HS and HS lists, Genespring GX 11.5 was used. For convenience, the 
probe lists containing significantly modified genes (fold change >= 2 and t-test P-
value <=0.05) in MC+HS- and HS-purified BV injected mouse brains will hereafter be 
mentioned as MC+HS and HS probe lists. Of the significantly modified probes in 
MC+HS and HS lists, a large number (353) were common to both as expected since 
BV is the major component of both formulations. Of the 353 probe IDs, one way 
Anova test with unequal variance followed by Tukey HSD post hoc test revealed 19 
probes (corresponding to 18 genes) to be differentially regulated (Table 3.4). The fold 
changes of these differentially regulated genes in HS probe list were remarkably 
higher compared to that in MC+HS probe list. Using DAVID, Gene Ontology – 
Biological Processes (GO-BP) that these genes participate in were obtained. Upon 
using Amigo Visualize Tool (http://amigo.geneontology.org/cgi-
bin/amigo/amigo?mode=visualize) on these GO-BPs, antiviral immune responses 
were found to be the major responses (Figure 3.6).  
Other than the commonly affected probes, there were 35 probes in MC+HS 
list and 77 probes in HS list. To gather information about the difference that the 
changes in these probes make to the host, Metacore from GeneGO was used. 
Metacore is an integrated software suite based on a manually curated database for 
functional and comparative analysis of microarray data across gene lists. Both lists 
were subjected to comparative enrichment analysis for various ontologies in 
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Metacore. Comparative enrichment analysis option in Metacore allows for the 
analysis of contribution of common and unique genes across the two gene lists to 
various ontologies. We restricted our focus to Gene Ontology (GO) processes and 
GeneGO pathways. Top 10 significantly affected GO processes and GeneGO 
pathways in MC+HS and HS are listed along with the contribution of common and 
unique genes to various ontologies in terms of negative log (P-value) in Figure 3.7A. 
The more the negative log (P-values), the stronger and more reliable are the chances 
for the ontology to be affected. The over represented GO processes with the most 
significant P-values included immune response, immune system response, defense 
response, cellular response to cytokine stimulus, response to cytokine stimulus, 
response to other organism, innate immune response, response to biotic stimulus, 
cytokine-mediated signaling pathway and multi-organism process. The fact that they 
were listed among the top 10 GO processes indicated that these were the most 
important biological changes that define the host responses to BV transduction in 
mouse brains. This is similar to our previously published results defining the 
responses of BV inoculation in the rat brain, human astrocytes and neurons (Boulaire 
et al., 2009).  
Comparative enrichment analysis for affected GeneGO pathways also 
revealed the top 10 significant pathways to be related to immune responses. 
Complement activation pathways topped the list across the two gene lists. 
Complement system consists of nearly 30 small proteins that can be activated 
through three pathways namely classical, alternate and lectin-binding complement 
pathway (Taylor et al., 1998). All three pathways were activated across the two lists. 
Other pathways significantly affected were involved in eliciting innate immune 
response to viral infection and resulting in interferon signaling and production 
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followed by antigen presentation by MHC class I molecules. The list of genes 
affected across various significant pathways and their fold changes are given in 
Table 3.5. Most of the genes from MC+HS were modified by lesser fold changes 
compared to those from HS. 
A close scrutiny at the graphs revealed that the contributions of the large 
number of genes common to both MC+HS and HS list towards the P-values of both 
GO processes and GeneGO pathways were highly significant. Apart from them, 
those genes unique to HS list contributed significantly to all top 10 GO processes. 
However, genes unique to MC+HS either did not contribute or contributed to a 
smaller extent to the P-values of GO processes compared to those genes unique to 
HS. Of the 10 significant GeneGO pathways, genes unique to HS contributed to the 
complement activation pathways, IFN alpha/beta signaling pathways and antigen 
presentation by MHC class I whereas genes unique to MC+HS did not participate in 
these pathways. These results suggested that genes from MC+HS list give rise to 
same immune responses elicited by the genes common to both MC+HS and HS list 
and the genes unique to MC+HS did not contribute to immune responses unlike the 




Fold Change  
HS vs Mock MC+HS vs Mock 
9530028C05 15.64 10.4 
BC013712 3.02 2.51 
C2 2.76 2.38 
Ctsc 3.79 3.04 
Gbp2 12.5 10.29 
Ifit2 18.78 13.02 
Igtp 16.41 12.11 
Tor3a 3.03 2.4 
Parp12 8.05 5.76 
Parp14 6.06 4.65 
Parp9 7.54 5.73 
Plac8 15.02 12.08 
Rsad2 18.53 12.92 
Slfn8 9.96 7.56 
Stat1 10.6 7.77 
Trim25 4.63 3.72 
Ugt1a 3.86 3.09 
Zc3hav1 5.66 3.95 
Table 3.4. Differentially expressed genes across HS and 
MC+HS gene lists and their fold changes. Probes common to HS 
and MC+HS list were analyzed by Genespring GX 11.5 for 
differentially expressed genes by one way Anova test with unequal 
variance followed by Tukey HSD post hoc. Fold changes of the 
various differentially expressed genes are represented. 
 
Figure 3.6. Treeview of Gene Ontology Biological Processes 
(GO-BP) that the differentially expressed genes in HS and 
MC+HS involved inSignificantly affected GO-BP from DAVID 
enrichment analysis were fed into Amigo Visualization Tool for 
obtaining the GO tree view. The P-values of the affected terms are 













Figure 3.7. Comparative enrichment analysis for GO processes and GeneGO 
pathways for significantly modified mouse genes. Significantly affected GO 
processes (A) and GeneGO pathways (B) indicated major host responses to 
baculovirus purified by the two methods. Significantly modified genes are those with 
fold changes ≥ 2 and t-test p-value ≤ 0.05. !
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GeneGO Pathways  
Fold Changes 
MC+HS HS 
Complement Pathways   
C3a/C3b/C3dg/C5 convertase/iC3b 13.88 18.81 
alpha-M/beta-2 integrin - 2.04 
alpha-X/beta-2 integrin - 2.04 
C5AR 2.90 2.72 
Factor B 8.71 7.62 
C1 inhibitor 5.61 6.15 
C1 - 2.07 
C1q - 2.07 
C1qRp 3.04 3.34 
C3 convertase (C2aC4b) 3.47 4.08 
C4b 2.72 2.97 
IgM -2.15 -2.20 
IFN a/b signaling pathway- P-value   
SOCS1 - 2.38 
SHP-1 2.09 2.45 
STAT2 2.58 2.62 
PML 2.18 2.75 
IRF9 3.65 4.26 
ISGF3 3.85 5.24 
STAT1/STAT2 3.85 5.24 
STAT1 3.85 5.24 
ISG15 10.22 11.25 
USP18 10.39 11.87 
ISG54 8.88 13.02 
Antigen presentation by MHC class I   
Immunoproteasome (11S regulator) 2.14 2.48 
Tapasin 2.62 3.52 
Beta-2-microglobulin 2.63 2.65 
TAP2 (PSF2) 7.25 8.17 
Immunoproteasome (20S core) 7.66 8.80 
TAP1 (PSF1) 8.69 8.31 
MHC class I 9.22 9.82 
PSME1 - 2.19 
PSME2 2.14 2.48 
PSMB8(LMP7) 7.66 8.80 
Antiviral actions of Interferons   
STAT2 2.58 3.25 
IRF9 3.65 4.26 
PKR 4.92 5.18 
STAT1 6.30 7.58 
ISGF3 6.30 7.58 
2'-5'-oligoadenylate synthetase 7.80 8.53 
OAS1 5.16 5.76 
OAS2 7.80 8.53 
HLA-A 9.22 9.82 




Oncostatin M signaling via JAK-Stat & MAPK in mouse and human cells 
OSM receptor 2.74 3.05 
SOCS3 4.86 5.38 
TIMP1 5.82 6.04 
STAT1 6.30 7.58 
SERPINA3 (ACT) 5.03 5.15 
CCL2 9.53 12.68 
Innate immune response to RNA viral infection  
I-kB 2.46 3.11 
RIG-I 4.18 6.42 
IRF7 6.06 6.26 
MDA-5 6.62 9.25 
LGP2 8.15 11.23 
TLR3 3.46 4.12 
Table 3.5. Significantly affected GeneGO pathways in MC+HS and HS purified 
BV innoculated mouse brains. Significantly modified genes (fold changes >= 2 and 
t-test p-value <= 0.05) from MC+HS and HS were subjected to comparative 
enrichment analysis for GeneGO pathways. Note the lesser number of genes and 
lesser fold changes of the affected genes in MC+HS compared to HS. 
3.8. Discussion 
The overriding objective of this chapter was to develop an efficient purification 
method for BV which can minimize insect cell contaminants thus eliminating much of 
the unwanted immune responses. The main finding of our study is that immune 
responses to BV decreased as the purity of the formulation increased. The method 
we developed met our objective as the purity of BV formulation in MC+HS method as 
shown by SDS-PAGE was much better than that obtained by HS method. It also 
yielded a decent recovery of more than 30% of total viral particles after the two-step 
purification process.  Recovery after purification by membrane chromatography was 
up to 94% in one of our experiments. Such high recoveries are possible only with 
membrane chromatography because it uses absorptive membranes with highly 
porous structures and active chemical groups attached to the surface of the 
membrane. The greater pore size offers more active surface area for binding of 
particles as large as viruses unlike column chromatography with resins or beads with 
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active surface areas contained within the small pores of the matrix. Also, the 
membranes are associated with shorter diffusion times compared to the resins or 
beads which are usually closely packed (Charcosset, 2006). Also, membrane 
chromatography allows for easy scale up. The mustang S cation exchange 
membrane chromatography unit used in this study has an open pleat of 16 layers of 
polyethersulfone (PES) membrane with pendant sulfonic functional groups and pore 
size of 0.8 μm which is larger than the size of BV. The binding of BV to the cationic 
membrane was mainly through gp64 protein (Wu et al., 2007). At slightly acidic pH of 
the endosomes, BV envelope is known to fuse with the host cell triggered by the 
conformational changes in gp64 (Blissard et al., 1992, Zhou et al., 2006). The same 
principle might apply here. At pH ≈ 6 (the pH of the Sf9 supernatant containing BV), 
gp64 protein is in its native conformation. When passed through the membrane, virus 
bound to it through gp64 proteins in its native conformation. Upon passing PBS of pH 
7.4, change in pH caused conformational changes in gp64 thus allowing the elution 
of BV. Since this method utilizes the conformational changes of BV gp64 for 
purification, besides BV purification, it can also be applied to purify other viruses 
psedotyped with gp64.  
However, the recovery varied largely depending upon the temperature of the 
BV supernatant passed through the chromatography unit. Maximum recovery could 
be obtained when the supernatant was at room temperature and the recovery 
decreased with the decrease in temperature suggesting that binding of virus to the 
membrane chromatography unit was stronger at lower temperatures thus decreasing 
the elution whereas the binding at room temperature was weak enough for the elution 
buffer to recover most of the viruses. Similar trend in baculoviral supernatant 
temperature playing a role in virus binding and  elution has been reported before in 
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concanavalin A chromatography for baculovirus purification (Chen et al., 2009b). The 
second step of high speed centrifugation not only concentrated the virus but also 
purified them by removing more proteins (Figure 3.4). Also, the lesser speeds used 
for centrifugation (28000 g) as against the ultra high speed of 80,000 g in sucrose 
gradient ultracentrifugation method resulted in little loss in infectivity. This method 
could be used for virus volumes up to 40 ml without much changes in recovery and 
scaling up to larger volumes awaits further investigation.  
Although other purification methods like size exclusion chromatography and 
multistep downstream processing involving the use of anion exchange membranes 
yield an overall recovery of   ~67% (Transfiguracion et al., 2007) and ≈ 38% (Vicente 
et al., 2009) respectively, our study is the first to establish the biosafety associated 
with a purification method in vivo using global gene expression profiling. MC+HS 
method brought significant changes only to 379 probes as against the 431 probes in 
HS method. Further analysis of these gene lists, in general, resulted in highly 
enriched immune response related GO processes and GeneGO pathway maps (as 
denoted by lower P-values) for genes in HS list than in MC+HS list. The lower the p-
value, the higher is the confidence that the effect is true and not by chance. In 
particular, BV purified by MC+HS method resulted in the elicitation of lesser number 
of genes with lesser fold changes in the complement pathways, interferon signaling 
pathway and antigen presentation by MHC class I (Table 3.5) suggesting that 
removal of contaminating proteins could be the reason for this. Thus, this chapter 
demonstrated the usefulness of MC+HS purification method in reducing the immune 
responses in vivo. 
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4. Host Responses to rBV inoculation into brains of non-
human primates  
4.1. Introduction and Aims 
With the successful demonstration of therapeutic effect of rBV expressing 
diptheria toxin A gene (Pieroni et al., 2001, Wang et al., 2006a) or HSV-tk gene  
under the control of cell-specific promoters (Balani et al., 2009, Wu et al., 2009) on 
rodent glioma xenograft models, hopes on rBV as gene delivery vectors for the 
treatment of gliomas or other central nervous system (CNS) disorders continue to be 
increasing. However, reports that baculovirus elicits immune responses in hosts (Abe 
et al., 2010) that sometimes nullify the transgene expression (Pieroni et al., 2001) 
question their suitability as gene delivery vectors for clinical trials. A complete 
understanding of the baculovirus-host interactions has not yet been established. The 
fact that limited information is available so far on the effects of baculoviral vectors on 
transduced mammalian cells at the molecular level necessitates the usage of high 
throughput analysis to clarify virus-host interactions. DNA microarray based gene 
expression profiling is one such technology that has been suggested to characterize 
host responses to viral-vector mediated transduction (Piersanti et al., 2004). The 
humungous data generated from microarray studies allow for the recognition of major 
pathways of virally induced responses and thus risk assessment of the vectors and 
identification of new target genes for specific viruses. Our laboratory has been 
applying DNA microarray technology that allows global gene expression profiling as a 
systems level approach in exploring host-BV interactions in human cell lines and rat 
models (Boulaire et al., 2009). Though rodents have been the experimental model for 
majority of the research groups to provide an insight into various research problems, 
especially the immune system, because of the differences in the time of evolution, 
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size and lifespan, they are not the same as humans. Variations in the structure, 
general characteristics, innate and adaptive immunity between mice and man have 
been reviewed in detail to caution the researchers about the possible differences in 
outcome (Mestas et al., 2004). This underscores the necessity of valid animal models 
to accurately evaluate the safety and efficacy of vectors designed for treatment of 
patients. 
 
Figure 4.1. Cynomolgous monkey (Macaca fascicularis).This macaque sharing 
high genome similarity with humans has become an important model for preclinical 
evaluation of viral-based gene therapy vectors. 
Non-human primates (NHPs), with their greater immunological and biological 
similarities to humans are in great demand as models for preclinical evaluation of 
highly specific biological therapeutics (t'Hart et al., 2003, Fiandaca et al., 2010). The 
most commonly used NHPs in research are Old World monkey species especially, 
rhesus and cynomolgus macaques (Macaca mulatta and M. fascicularis (Figure 4.1)), 
the common ancestor of which and man dates back to 25 million years ago (Gibbs et 
al., 2007). This evolutionary proximity has reflected a high degree of similarity 
between man and macaques at the level of polymorphic gene families, such as those 
encoding major histocompatibility complex or T-cell receptor molecules or 
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immunoglobulins, and also leukocyte surface molecules and immune regulatory 
molecules, such as cytokines and chemokines (Bontrop et al., 1995, Bontrop et al., 
1999). Also, the draft genome sequence of rhesus macaque published in 2007 
(Gibbs et al., 2007) transforms the animal from a physiological model in to a “whole-
organism system”. Together with these, the fact that both humans and NHPs can be 
infected with similar types of viruses and that infections often follow a similar course 
makes NHPs important models to study virus-based constructs for gene therapy. 
Thus, envisaging the advancement of baculoviral vectors into clinical trials as gene 
delivery vectors to treat CNS disorders, this chapter aims to understand baculovirus-
host interactions at the molecular level in non-human primates’ brains and evaluate 
the toxicology of BV upon acute central administration. 
4.2. BV-tk inoculation into macaque brains considerably alters gene 
expression 
Three cynomolgous monkeys (Macaca fascicularis) – 5A5C, 557A and 5D0D 
were used for this study. Having verified the improved safety associated with MC+HS 
purification method and the therapeutic efficacy of recombinant baculovirus 
accommodating HSVtk gene under the control of GFAP promoter and appended to 
three repeats of three micro RNA sequences (hsa-miR-31, hsa-miR-127 and hsa-
miR-143) shortly referred to as BV-tk to treat gliomas in mice models (Wu et al., 
2009), BV-tk purified by MC+HS method was used to assess the host responses 
upon acute central administration into macaque brains. Four injections each 
containing 108 pfu of test virus was injected into right hemisphere against the mock 
supernatant purified by MC+HS method into the left hemisphere. After 48 hours, the 
samples were collected and successful injection of virus into macaque brains was 
verified by real time PCR for gp64 on one of the four test virus injected brain samples 
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against its corresponding control in each animal (Figure 4.2). All three virus injected 
brain samples tested positive for gp64 but with varying copy numbers. Differences in 
the copy number may be attributed to the differences in the sample collection (a bit 
further away from the injection site) or processing of the tissues for measuring gp64 
copy number. 
 
Figure 4.2. Confirmation of successful injection of rBV-tk into macaque brains 
by real time-PCR analysis for gp64. In all three animals, one of the four BV-tk 
injected brain samples and their corresponding control brain samples were analyzed 
for the presence of virus. 
Gene expression profiling in response to BV-tk inoculation in to macaque 
brains was examined using Affymetrix GeneChip Rhesus Macaque Genome Array 
that provides a comprehensive coverage of the transcribed rhesus genome, 
comprising 52,024 probe sets for approximately 47,000 Macaca mulatta transcripts. 
Two pairs of samples, BV-tk-injected and mock-injected brain tissues from each 
animal with a total of 6 samples each in BV-tk-injected and mock-injected category 
























probes on the chips were called present in the virus-injected and mock-injected brain 
samples. After performing quality control based on expression and flags, 205 probes 
(0.39%) were observed to show two or more folds difference in expression and to be 
statistically significant (t-test, p-value ≤ 0.05) between the BV-tk-injected and mock-
injected samples. This set of genes represented 184 up regulated and 21 down 
regulated probes with 171 IDs recognized by DAVID Bioinformatics 6.7. Microarray 
data analysis by GenespringGX 11.5 from Agilent Technologies is summarized in 
Table 4.1. 
Microarray Chip Used 
Affymetrix GeneChip 
Rhesus Macaque Genome 
Array 
Total No. of Transcripts present 52,865 
Total No. of transcripts examined 
(present/marginal) 25491 
Probes modified (2 fold 
change+p<0.05) 205 
Probes Upregulated 184 
Probes Downregulated 21 
% of modified genes 0.39 
Table 4.1. Summary of Microarray Data Analysis on macaque brains inoculated 
with MC+HS purified BV by Genespring GX11.5 
4.3. Validation of microarray results by real time PCR assay 
To validate the findings from microarray analysis, real time PCR assays were 
carried out on 9 genes – MDA5, ISG-15, IL-15, TAP-1, MAMU-A, MAMU -E, MAMU-
F, C1S and FCGR3. The selection was made in such a way that genes from 
important KEGG pathways were validated. The various KEGG pathways involving 




RIG-1 like receptor signaling pathway – MDA5, ISG-15 and IL-15 
Antigen presentation and processing - TAP1, MAMU-A, MAMU -E and MAMU -F 
Complement and coagulation cascades – C1S 
Fc gamma R-mediated phagocytosis – FCGR3 
Rhesus GAPDH was used as an internal normalization control. All of the 
selected genes displayed similar trend in up or down regulation (Figure 4.3) 
consistent with those from the microarray analysis even though the actual fold 
changes were not identical. 
 
Figure 4.3. Validation of fold changes in expression by microarray using 
quantitative real time PCR assay for macaque genes. Nine of the significantly 
modified (fold changes >= 2 and t-test p-value <= 0.05) genes from macaque brains 
participating in different KEGG pathways were analyzed. Genes in purple - RIG-1 like 
receptor signaling, genes in red -  Antigen Presentation and Processing, genes in 
green - Complement and Coagulation Cascades, genes in blue - Fc gamma R-
mediated phagocytosis. Rhesus glyceraldehyde-3-phosphate dehydrogenase 









































4.4. rBV inoculation into macaque brains elicits antiviral immune 
responses 
To obtain the biological meaning of significantly modified genes in MC+HS 
purified BV-tk injected macaque brains, the web-based services, DAVID 
Bioinformatics Resources v6.7 and Metacore from GeneGO were used. The resultant 
probe list containing 205 IDs was fed into Metacore to gather insights into the GO 
processes and GeneGO pathways responsive to BV-tk inoculation in macaque 
brains. The top 10 significantly affected GO processes included immune response, 
defense response, immune system process, innate immune response, type I 
interferon-mediated signaling pathway, cellular response to type I interferon, 
response to type I interferon, interferon-gamma-mediated signaling pathway, 
cytokine-mediated signaling pathway and cellular response to interferon-gamma.  
Upon visualizing them on Amigo Visualize tool (http://amigo.geneontology.org/cgi-
bin/amigo/amigo?mode=visualize), all 10 GO processes were eventually either a 
response to stimuli or a part of immune system process (Figure 4.4). Also, in an 
attempt to map the significantly affected genes to various GeneGO pathways, seven 
out of the top 10 significantly affected pathways were observed to be involved in 
immune response elicitation (Figure 4.5). The pathways included Lectin induced 
complement pathway, classical complement pathway, antiviral actions of IFNs, IFN 
alpha/beta signaling pathway, innate immune response to RNA viral infection, 
antigen presentation by MHC class I and IL-5 signaling.  These results indicated that 
antiviral immune responses were the major responses to BV inoculation in the brains 
of non-human primates.  
Upon using DAVID to map significantly genes to KEGG pathways, three 
immune response related pathways namely antigen presentation and processing (P-
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value= 4.30E-05), RIG-1 like receptor signaling pathway (P-value= 2.81E-03) and 
cytokine-cytokine interactions (P-value= 6.50E-02) were found to be majorly elicited. 
In agreement with the notion that astrocytes and microglial cells of the brain present 
antigens and stimulate T-cells (Aloisi et al., 2000), 13 genes from antigen processing 
and presentation pathway were found to be upregulated (Table 4.3). RIG-1 like 
receptors (RLRs) are a class of pathogen recognition receptors (PRRs) including 
RNA helicases like RIG-1, MDA5 and LGP2 that reside in the cytoplasm of immune 
and non-immune cells and recognize viral RNA species produced in the cytoplasm. 
RLRs are known to induce type I interferon (IFN) production through an adaptor 
molecule IPS-1 that localizes in the mitochondria (Kawai et al., 2005). LGP2 serves 
as a negative or positive regulator of RIG-1 and MDA-5 depending on the type of 
RNA viruses (Venkataraman et al., 2007). In macaque brains, five of the RLR 
pathway genes were up regulated and one down regulated (Table 4.2). Apart from 
IFN production, activation of PRRs in antigen presenting cells also leads to the 
production of immunologic messenger molecules - cytokines and chemokines, that 
interact with their respective receptors to bring about more innate and adaptive 
immune responses. Four cytokine genes were found to be upregulated in macaque 
brains (Table 4.3). 
  
 
Figure 4.4. Tree view of 
significantly affected Gene 
Ontology - Biological 
Processes (GO-BP) in 
MC+HS purified BV-tk 
injected macaque brains 
samples. Top 10 significantly 
affected GO-BP from 
GeneGO enrichment analysis 
were fed into Amigo 
Visualization Tool for 
obtaining the GO tree view. 
The P-values of the affected 

















Figure 4.5. Significantly affected GeneGO pathways in BV-tk injected macaque 
brain samples. List of significantly affected genes in macaque brain upon BV 
inoculation was fed into Metacore for enrichment analysis using the default threshold 
for P-values. Top 10 significantly affected GeneGO pathways are presented here 
along with their negative log P-values.* indicates immune response related 
pathways. Note that immune response related pathways are dominant in the top ten 
pathways. 
4.5.  Differential responses to rBV inoculation in macaque and mouse 
brains 
Though BV-tk elicited immune responses in macaque and mouse brains, 
remarkable differences were observed in the type of immune responses and 
interferon production pathways, which are discussed below 
4.5.1.  Interferon production pathway 
In both macaque and mouse, interferon (IFN) production pathways were 
activated as an innate immune response to BV-tk inoculation. Induction of interferon 
production can occur as a result of activation of different PRRs. A close scrutiny of 
genes involved in the GeneGO pathway – Innate Immune responses to RNA viral 
0 2 4 6 8 10
*IL-5 signalling
Transcription regulation of granulocyte development
Angiotensin signaling via STATs
*Innate immune response to RNA viral infection
*Antigen presentation by MHC class I
Thrombopoetin signaling via JAK-STAT pathway
*IFN alpha/beta signaling pathway
*Antiviral actions of Interferons
*Classical complement pathway




infection across macaque and mouse MC+HS gene list revealed that none of the 
TLR genes were significantly modified in eliciting innate immune responses in 
macaque brains (Table 4.3). This may suggest that TLR independent pathway may 
be involved in the induction of IFN production. To gain insight into the particular 
pathways that result in IFN induction, mouse and macaque gene lists were mapped 
to various KEGG pathways using DAVID bioinformatics. Significantly modified genes 
(fold change ≥2 and P-value ≤0.05) from mouse mapped to three interferon 
production inducing pathways namely Toll-like receptor (TLR) signaling, RIG-1 like 
receptor (RLR) signaling and cytosolic DNA sensing pathway whereas, gene list from 
macaque mapped only to RLR pathway (Figure 4.6) suggesting that RLR signaling is 
the major pathway of interferon production upon rBV inoculation in macaque brains. 
 
Figure 4.6. Interferon production pathways affected in mouse and macaque 
brains upon BV-tk innoculation. Significantly modified genes from mouse and 
macaque brains were subjected to DAVID analysis for enriched KEGG pathways. 
Note that only RIG-1 like receptor signaling pathway was affected in macaque brains 
whereas three pathways were affected in mouse brains upon BV-tk injection. 
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Gene Symbol Mouse Macaque 
RIG-1 like receptor signaling pathway p-value  3.62E-04 2.81E-03 
CXCL10 15.46 - 
IL-8 - 2.21 
IRF7 6.06 - 
ISG15 10.22 12.19 
LGP2 8.15 - 
MDA5 6.62 3.99 
POLR3C - -2.13 
RIG1 3.77 3.85 
STING 2.02 - 
TRIM25 3.42 2.69 
Cytosolic DNA-sensing pathway p-value  9.38E-05   
RIG1 4.18 
 IFI202B 19.29 
 STING 2.02 
 IRF7 6.06 Pathway 
not affected PYCARD 2.23 
CCL5 (RANTES) 55.13 
 DAI 12.99 
 CXCL10 15.46 
 Toll-like receptor signaling pathway p-value  3.36E-03!   
MYD88 2.01 
 IRF7 6.06 
 TLR2 2.44 
 TLR3 3.46 Pathway 
not affected TLR4 2.12 
CCL5 55.13 
 STAT1 4.93 
 CXCL10 15.46   
Table 4.2. Interferon production pathways affected in mouse and macaque 
brains upon BV-tk innoculation. Significantly modified genes (expression level ≥ 
two-fold and t-test p-value of ≤ 0.05) from mouse and macaque brains were 
subjected to DAVID analysis for enriched KEGG pathways.  Fold changes of the 
various genes affected in the mentioned KEGG pathways are represented. 
4.5.2. Major histocompatibility molecules 
BV-tk induced antigen processing and presentation pathway in both macaque 
and mice brains. In macaque brains, antigen processing and presentation pathway 
involved both class I and II molecules of major histocompatibility molecules (MHC) 
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whereas in mouse brains, it involved only MHC class I molecules. Analysis by DAVID 
Bioinformatics for enriched KEGG pathways revealed this. The list of significantly 
modified genes involved in these pathways together with their fold changes are listed 
in Table 4.3. 
4.5.3. Cytokines and chemokines 
Another remarkable difference between mice and macaque responses to BV-
tk inoculation was in the type and number of cytokines and chemokines. Chemokines 
are a class of small cytokines secreted by immune cells with immunomodulatory and 
chemo-attractive properties to recruit immune cells to the site of viral infection. In 
mice, 13 chemokine and 7 chemokine receptor genes were significantly up regulated 
suggesting the effective amplification of chemokine genes to recruit immune cells to 
the site of infection. However, in macaque brains, only four cytokines were 
significantly up regulated (Table 4.3).  
These results suggested that macaque brains respond to BV by inducing 
interferon production through a TLR-independent RLR signaling pathway and that the 
injected dose of baculovirus per injection site did not elicit stronger immune 
responses and produced only fewer cytokines than in mouse. 
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Gene Symbol Mouse Macaque 
RIG-1 like receptor signaling pathway (GeneGO pathway) 
I-kB 2.46 - 
IL-8 - 2.21 
IRF7 6.06 - 
LGP2 8.15 - 
MDA-5 6.62 4 
RIG-I 4.18 3.35 
TLR3 3.46 - 
Antigen Processing and Presentation (KEGG pathway) 
MHC class 1 
(H2-Q6/H2-Q7)/HLA-B 13.4 2.52 
(H2-T10/H2-T22)/- 6.09 - 
B2m/B2M 2.52 - 
Cd74/CD74 - 3.42 
H2-D1/HLA-C 6.41 2.52 
H2-Ea/HLA-DRA - 2.86 
H2-K1/HLA-C 6.87 2.52 
H2-M3/HLA-G 2.91 5.21 
H2-M5/MAMU-F - 2.21 
H2-Q8/- 6.87 - 
H2-Q10/MAMU-B18 - 3.21 
H2-Q10/MAMU-I - 3.36 
H2-T23/MAMU-E 7.5 3.18 
H2-T24/- 3.62 - 
H2-T9/- 13.4 - 
H2-Dma/LOC717870 - 2.12 
Psme2/- 2.14 - 
Tap1/TAP1 8.69 3.29 
Tapbp/- 2.41 - 
Tap2/TAP2 7.25 - 
MHC class II 
H2-Dma/LOC717870 - 2.12 
H2-Ea/HLA-DRA - 2.86 
Ifi30/LOC719379 - 2.4 
Cytokines-Cytokine receptor interaction 
CCL12 (MCP-5) 9.53 - 
CCL2 (MCP-1) 12.5 - 
CCL5 (RANTES) 55.13 - 
CCL6 (MRP-1) 2.61 - 
CCL9 (MRP-2) 3.24 - 
CCR6 (CD196) -2.04 - 
CLCF1 (BSF-3) 2.71 - 
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CSF1 (MCSF) 2.17 - 
CSF2RB2 (IL-3R) 2.19 - 
CXCL10 (IP-10) 15.46 - 
CXCL12 -2.32 - 
CXCL13 (BCA-1) 3.99 - 
CXCL16 2.47 - 
CXCL2 (MIP-2) 3.24 - 
IL2RG 4.94 - 
IL4RA 2.72 - 
OSMR 2.74 - 
TNFRSF12A 2.21 - 
TNFRSF1A 2.03 - 
TNSF10 2.07 !IL15 - 2.44 
CXCL11 - 5.29 
TNFSF13B - 4.53 
IL8 - 2.21 
Table 4.3. Differential Responses of mouse and Macaque brains to baculoviral 
transduction. Fold changes are shown for genes with expression level >= two-fold 
difference between baculovirus injected mouse and Macaque brains samples and 
corresponding control samples and a t-test p-value <= 0.05. 
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4.6. Toxicology and behavioral assessment of rBV vectors in non-
human primates 
To evaluate the toxicology and behavioral effects of rBV-tk following acute 
central administration in macaques, the animals were observed for various tests 
listed in Table 4.4 before and after virus injection. During the observation period of 48 
hours after test virus injection, there was no death, abnormal clinical signs or 
behavioral changes in any animal (Table 4.5). There were no major changes in body 
weights (Table 4.6). Gross pathological findings also showed no detectable 
abnormality (Table 4.7). Urinalyses performed pre and post injection just before 
necropsy showed no abnormality (Table 4.8). Blood, liver and kidney samples tested 
negative for baculovirus by real time PCR assay for gp64 (data not shown). Also, 
histopathology report revealed no rBV-associated lesions in any of the tissues 
examined including brain (Figure 4.7). These data suggest that baculovirus has a 
good safety profile with minimal to no toxicity in macaque. 
Observations Results –  3 Macaque 
Mortality None 
Clinical 
Observations No abnormality 
Body weight 
Measurement data No major change 
Haematology and 
Coagulation Normal 
Clinical Chemistry Normal 
Urinalysis Normal 
Gross pathology No abnormality 
Histopathology No test article associated histopathologic lesions 
Table 4.4. Summary of toxicology assessment of 
BV-tk vectors in macaque brains. 
 
Figure 4.7. Representative images of 
Haematoxylin and Eosin stained brain sections 




Day 1 Day 2 
5A5C NA NA 
557A NA NA 
5D0D NA NA 
NA - No Abnormality Noted 
Table 4.5. Clinical Observations of Individual Animals 
Animal No. 
Body Weights (kg) 
Pre-Dose Day 2 
5A5C 2.98 2.86 
557A 2.99 2.87 
5D0D 2.67 2.73 






No Abnormality Detected 
Table 4.7. Gross Pathological Findings 
Mock-injected ! BV-tk-injected !






Appearance VOL (ml) SG pH PROT GLU KET BIL ERY UBG LEU (Leu/ul) 
5A5C Light yellow / clear 5.5 1.015 9 neg norm neg neg neg norm 25 
557A Straw / 5.5 1.006 8 neg norm neg neg neg norm neg sl turbid 
5D0D Light yellow / sl turbid 5 1.01 6 neg norm neg neg neg norm neg 
Day 2- Post Dose 




Appearance VOL (ml) SG pH PROT GLU KET BIL ERY UBG LEU (Leu/ul) 
5A5C Light yellow / clear 11 1.019 8 neg norm neg neg 25 norm neg 
557A Straw / 5.5 1.013 9 neg norm neg neg neg norm neg sl turbid 
5D0D Light yellow / sl turbid 5.5 1.012 9 neg norm neg neg neg norm neg 
Table 4.8. Urinanalysis pre and post rBV dose.  
VOL – Volume; SG - Specific Gravity; PROT – Protein; GLU – Glucose; KET – Ketone; BIL – Bilirubin; ERY - Blood Pigments; UBG – 





The primary objective of this study was to understand the host responses and 
evaluate the toxicity in macaque brains to BV innoculation. Once inside the immune 
competent cell, BVs are recognized by pathogen recognition receptors (PRRs) like 
membrane bound TLRs and cytoplasmic RLRs. TLRs are the most well studied PRRs 
with respect to viral infections (Kawai et al., 2008). Upon infection, TLRs follow MyD88 
dependent pathway to activate NFκB and c-Jun, the transcriptional regulators of a number 
of chemokines and cytokines responsible for cellular immune response (Wang et al., 
2001). Endosomal TLRs (TLR-3, 7, 8 and 9) are traditionally associated with viral 
recognition (Brennan et al., 2010) while cell membrane bound receptors TLR-2 and TLR-4 
are involved in interacting with the viral envelope glycoproteins (Barton, 2007). 
Baculoviruses are known to induce type I IFNs in immune cells like peritoneal 
macrophages (PECs), splenic CD11c+ DCs and murine macrophage line RAW264.7 
through TLR-9/MyD88-dependent pathway (Abe et al., 2005). However, treatment of 
PECs with endosomal inhibitors failed to stop type I IFN production suggesting the 
existence of TLR-9 independent pathways (Abe et al., 2009). Recently, Chen and 
colleagues reported that baculoviruses can induce type I IFN production in mesenchymal 
stem cells through TLR-3 dependent pathway (Chen et al., 2009a). We have 
demonstrated through microarray studies that neurons, which do not possess TLR-9, 
respond to BV inoculation by producing IFNs through TLR-3 dependent pathway. In rat 
brains, TLR2 is involved in IFN production (Boulaire et al., 2009). In this study, TLR-2, 3 
and 4 were up regulated in the mouse brain (Table 4.2) suggesting the recognition of 
envelope glycoproteins by TLR-2 and TLR-4 and genomic DNA or transcribed RNA 
products by TLR-3. IFN-β secreted as a result of TLR induction acts on neighboring cells 
and activates Jak-STAT pathway via IFN receptor to induce the expression of IFN 
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regulatory factor 7 (IRF7) which may result in the amplification of type I IFN through a 
positive feedback mechanism (reviewed in Kawai et al., 2008). STAT1 and IRF7 were 
also up regulated in this study (Table 4.2). However, none of the TLRs were significantly 
modified in virus injected macaque brain samples (Table 4.2 & Table 4.3) suggesting the 
involvement of a TLR independent pathway in the induction of IFN production in the 
macaque brains. 
RLRs are a second class of PRRs including RNA helicases like RIG-1, MDA5 and 
LGP2 that reside in the cytoplasm of immune and non-immune cells and recognize viral 
RNA species produced in the cytoplasm. RLRs are known to induce type I IFN production 
through an adaptor molecule IPS-1 that localizes in the mitochondria (Kawai et al., 2005). 
LGP2 serves as a negative or positive regulator of RIG-1 and MDA-5 depending on the 
type of RNA viruses (Venkataraman et al., 2007). In this study, RIG-1 (DDX58), LGP2 
(DHX58) and several other genes in RLR pathway were found to be up regulated (Table 
4.3) suggesting its involvement in IFN production upon baculoviral transduction in mouse 
brains. In macaque brains, STAT1 (fold change = 2.17) and RLR pathway genes - RIG-1, 
ISG15, MDA5, IL-8, POLR3C and TRIM25 were up regulated. This may suggest that RLR 
pathway is the major IFN production pathway in macaque brains. Though not many 
studies have demonstrated the involvement of RLRs in baculoviral transduction, a recent 
study has noted that RIG-1 and MDA5 mRNA levels were elevated in baculovirus-
transduced cells (Wang et al., 2010b). Involvement of RLR signaling pathway in BV 
transduction is a relatively new field ready for exploration.  
TLR-3 and RLR signaling have so far been associated with the recognition of 
double and single stranded RNA. A common query that would strike any researcher is 
how baculovirus accommodating double stranded DNA could be recognized by PRRs 
recognizing RNA molecules. One possible explanation given by Chen and colleagues was 
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that the immediate early gene products expressed by baculovirus upon entry into 
mammalian cells could be recognized by RNA recognizing PRRs (Chen et al., 2009a). 
Recently, RLR pathway was demonstrated to contribute to IFN responses activated by 
cytosolic DNA as well (Kim et al., 2009a). The two RLRs - RIG-1 and MDA-5 act as non-
redundant cytosolic DNA receptors resulting in the direct activation of IRF3 leading to the 
induction of IFN. This suggests that RLRs can recognize BV DNA as such excluding the 
need for the transcribed immediate early gene to elicit immune responses. Furthermore in 
mice, other cytosolic DNA sensors like DNA-dependent activators of IRFs (DAI) and 
stimulator of IFN genes(STING) which have been identified to play roles in IRF activation 
and IFN production (Choi et al., 2009) were upregulated. 
PRR triggering leads to the production of different immunologic messenger 
molecules like IFNs, cytokines and chemokines. Chemokines are secreted by immune 
cells and possess immunomodulatory and chemo-attractive properties to recruit immune 
cells to the site of viral infection. In the current study, as a result of BV inoculation, 13 
cytokines and 7 cytokine receptors have been up regulated in mouse brains and 4 
cytokines in macaque brains, suggesting that active recruitment of immune cells to the 
site of infection is low for the given dose of 108 pfu BV per injection site and over the given 
observation period of 48 hours. Upregulation of IL-2Rγ in mouse brains and IL-15 in 
macaque brains may indicate the induction of host adaptive immune responses to BV 
inoculation. IL-2Rγ is shared by cytokines IL-2 and IL-15 both of which are T-cell growth 
factors. IL-2 plays an important role in adaptive immunity by generating and maintaining 
Treg cells whereas IL-15 is involved in maintaining the survival of CD8+ memory T cells 
(Commins et al., 2010). BV transduction of bone marrow derived DCs has been shown to 
up regulate MHC class I and II molecules and co-stimulatory molecules CD40, CD80 and 
CD86 (Suzuki et al., 2010).  Signals sent out by these molecules can eventually induce 
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the simultaneous secretion of IL-2 and the expression of high-affinity IL-2R on the effector 
T-cells (Thornton et al., 2004) thus inducing adaptive immune responses.  
In spite of all these immune responses, baculoviruses are generally viewed as 
gene delivery vectors with a good safety profile compared to other vectors and 
experimental evidences for the same have been mounting for years now. Even though 
baculoviruses co-exist with humans in close proximity, so far, there are no evidences for 
them to infect hosts other than insects. No baculovirus neutralizing antibodies were 
detected in human serum samples whereas adenovirus neutralizing antibodies were 
detected in 65% of the humans tested. Also, the immunogenicity of baculovirus is 
relatively lower as indicated by the induction of lower number of T-cells compared to 
adenovirus (Strauss et al., 2007). Feeding or intraperitoneal injection of live nuclear 
polyhedrosis viruses (NPVs) and granulosis viruses (GV) to mice and hamsters did not 
cause chromosomal aberrations or sister chromatid exchanges in rapidly dividing bone 
marrow cells unlike other mammalian viral vectors (Reimann et al., 1982). In another 
study, guinea pigs and mice tested with high doses of polyhedral or free baculovirus rods 
for intradermal allergenicity, intranasal and intravenous administration confirmed the 
safety associated with these viruses (Heimpel, 1966). NPVs tested for propagation, 
immune reactions and acute infections in pigs of commercial and agricultural importance 
demonstrated a good safety profile (Doller et al., 1983). A recent study evaluated the 
safety of Bombyx mori (another widely known baculovirus)-based vaccines in rhesus 
macaques and reported its safety even at high doses (Jin et al., 2008). However, 
toxicology studies of replication defective adenoviral vectors was associated with lethargy 
and death within 1 hour post-high dose upon intravenous injection in rats (Morrissey et al., 
2002b) and acute cardiovascular and hemodynamic effects upon intrahepatic injection in 
pigs (Morrissey et al., 2002a). Moreover, our study to assess the toxicology of AcMNPV in 
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macaque brains has also guaranteed its biosafety profile in spite of the immune 
responses mounted against baculovirus at the molecular level. Significant modifications in 
0.39% of the total probes did not bring about any behavioral changes thus highlighting the 
safety associated with them. Also, considerably less immune response were elicited in 
macaque brains for the same dose of 108 pfu/injection site compared to mouse brains 
suggesting that BV may be safer to higher animal models than rodent models. 
In this study, however, we have observed the response in macaque brains only 
upon single injection of BV for a time span of 48 hours. This pilot study may not be 
sufficient to provide a comprehensive understanding of the host brain response to BV. For 
instance, single higher dosing or multiple dosing of viral vector to achieve the therapeutic 
effect may activate the immune system more, eventually compromising the therapeutic 
effect. The degradation time of BV in macaque brains can be figured out only by 
observing the animals for a longer time period. Also, the toxicity may vary upon repeated 
injections. To answer these unknowns and to further the understanding of host brain 
response to BV, in future, a dose-dependent (4x108 pfu/ml and 4x109 pfu/ml) study for 
extended time point (14 days) and multiple dosing (3 BV inoculations at an interval of 2 
weeks) study will be carried out. 
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5. Cationic Lipid Coating Improves Serum-Resistance in 
Recombinant Baculovirus 
5.1. Introduction 
Despite the efficient transducing ability in a wide variety of quiescent and non-
quiescent mammalian cells including embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPS), in vivo gene delivery by recombinant baculovirus (rBV) is 
known to be hampered by its susceptibility to complement-mediated inactivation (Sandig 
et al., 1996, Hofmann et al., 1998, Hofmann et al., 1999, Kaikkonen et al., 2011). 
Complement system consists of nearly 30 small proteins contributing to specific or non-
specific immune reactions. Upon encountering foreign bodies like viruses, the 
complement system initiates a series of enzymatic reactions eventually resulting in their 
inactivation and lysis of infected cells. In the case of BV based gene delivery, 
complement-mediated immune reactions either reduced or shut down the transgene 
expression (Hofmann et al., 1995, Sandig et al., 1996, Pieroni et al., 2001). Sometimes, 
the immune reactions may be too strong resulting in serious tissue damage and systemic 
immune response. Therefore, to achieve efficient transduction and minimize the immune 
reactions, it is necessary to improve the serum resistance of rBV or camouflage it from 
the complement system. 
Several strategies have been developed to overcome this hurdle and improve the 
serum-resistant capacity of rBV vectors. This is discussed in (Kaikkonen et al., 2011). 
One of the commonly used strategies to prepare rBV capable of withstanding the serum 
complement system is the genetic modification of BV. Genetically modifed BV with the 
complement regulatory protein - human decay accelerating factor (DAF) incorporated into 
its envelope had improved transduction efficiency in complement sufficient neonatal rats 
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upon direct injection into the liver parenchyma (Huser et al., 2001). However, the injection 
did not bring about successful transduction in adult rats and BV-DAF could not be 
produced in sufficient titres as the DAF protein in the envelope interfered with its normal 
replication cycle (Huser et al., 2001, Hoare et al., 2005). Also, genetically modified BV 
possessing vesicular stomatitis virus envelope glycoprotein  (VSVG) demonstrated 
increased resistance to inactivation by animal sera in vitro but failed in in vivo studies 
upon intravenous, intraperitoneal or intrahepatic routes (Tani et al., 2003). Second 
commonly used strategy is the inhibition of complement proteins at the site of virus 
delivery. Though the use of soluble complement inhibitor (sCR1) increased the survival of 
BV in human serum (Hoare et al., 2005), suppressing the immune system might lead to 
other complications.  
Recently, the use of hybrid vectors formed by merging viral and non-viral vectors 
has been suggested as the best possible solution to overcome the viral-vector associated 
hurdles (Boeckle et al., 2006). Hybrid vectors are an attempt to merge the complementary 
strengths of viral vectors – the high transduction efficiency and that of non-viral vectors - 
low immunogenicity and high systemic potential. Formation of hybrid vectors can 
otherwise be called as chemical modification of viruses as it involves the use of non-viral 
vectors like polymers or lipids that are chemicals. Hybrid vectors have proved successful 
in producing synergistic effects (Boeckle et al., 2006). Especially, when the non-viral 
component of the hybrid vector is conjugated to a ligand having receptors on target cells, 
enhanced targeting is taken care of while the viral component looks after the enhanced 
transduction efficiency (Wagner et al., 1992, Kim et al., 2009b). rBV have been used with 
polymers like polyethylene glycol (PEG) and polyethyleneimine (PEI) in vitro and in vivo to 
achieve enhanced transduction efficiency and resistance to serum complement system. 
Evidences that cationic lipids enhance adenoviral infection efficiency of several cell lines 
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including primitive human hematopoietic cells (Byk et al., 1998) and augment gene 
transfer to cerebral arteries in vivo (Toyoda et al., 2001) turned our attention towards them 
as the non-viral counterparts to merge with rBV to form hybrid vectors that can evade the 
complement mediated attack. With the improvised versions of cationic lipids - 
Lipofectamine 2000 and Cellfectin II that can deliver genes into mammalian cells in the 
presence of serum, we reasoned that coating rBV with these lipids could help rBV escape 
the complement mediated inactivation and achieve efficient transduction. Therefore, this 
chapter aims to test this hypothesis. 
5.2. Formation of cationic lipid coated BV 
 
Figure 5.1. Schematic representation of cationic lipid coating on recombinant 
baculovirus. The electrostatic interaction between the negatively charged viruses and 
positively charged cationic lipids results in the hybrid vector formation. 
Hybrid vectors combining rBV and cationic lipids were formed by mixing rBV and 
appropriate amounts of cationic lipids and incubating for 20-30 minutes at room 
temperature. The electrostatic interaction between the negatively charged BV and the 
+
Cationic lipids Baculovirus (BV)
Cationic Lipid coated BV
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positively charged cationic lipids aided in the hybrid vector formation. 
Schematic representation of the interaction between BV and cationic lipids is represented 
in Figure 5.1. 
5.3. Zeta potential and size characterization of uncoated/cationic lipids 
coated BV  
rBV encoding luciferase gene (BV-luc) was used all through out the experiments of 
this chapter and the terms rBV and BV-luc are used interchangeably. To understand the 
interaction between rBV and cationic lipids - Cellfectin II and Lipofectamine 2000 and to 
optimize the amount of lipids to coat rBV, uncoated/cationic lipids coated BVs were 
characterized for their zeta potential using laser Doppler electrophoresis and size using 
dynamic light scattering (DLS) on a Zetasizer. At neutral pH, BV in water was negatively 
charged with a zeta potential of ~-20 mV. As the number of molecules of cationic lipids 
used to coat BV increased, the zeta potential of the samples moved towards zero and 
increased further to ~+15 mV and ~+22 mV at 107 molecules of Cellfectin II and 
Lipofectamine 2000 respectively per rBV particle (Table 5.1). This drastic change in zeta 
potential upon addition of cationic lipids indicated the strong electrostatic interaction 
between them and the virus particles. 
Uncoated rBV measured a hydrodynamic diameter of ~407 nm. This was more 
than the dimension of BV in the literature which is  ~300 nm. This difference could be 
explained by the fact that hydrodynamic diameter of the virus particle is influenced by 
hydration and solvation effects unlike size measurements using transmission electron 
microscopy (TEM), where the virus sample is a dehydrated hard sphere. Upon addition of 
varying amount of cationic lipids, the size of the complex increased gradually indicating 
the coating of lipids on to BV. Z.average (intensity weighted harmonic mean size) peaked 
at ~5557 d.nm for Cellfectin II coated BV at a ratio of 7.5x106 molecules/virus particle and  
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~8262 d.nm for Lipofectamine 2000 coated BV at a ratio of 2.5x106 molecules/virus 
particle. This sharp increase in size was an indication of particle aggregation. Particles 
with zeta potential in the range of -20 mV to +20 mV tend to aggregate and the degree of 
aggregation depends on the proximity of zeta potential value to neutral zeta potential 
value. When the amount of cationic lipids was increased further, the size decreased, 
following the increased zeta potential that increased the electrostatic repulsion to form 









(mV) in Water 
BV-luc 
   0 407.07 ± 5.5 0.42 ± 0.03 -19.7 ± 0.5 
BV-luc-Cellfectin II 
  1.00E+05 430.63 ± 30.66 0.4 ± 0.03 -19.93 ± 0.31 
1.00E+06 1159.67 ± 42.36 0.44 ± 0.03 -13.93 ± 0.23 
2.50E+06 2757.67 ± 83.39 0.45 ± 0.01 -9.31 ± 0.25 
5.00E+06 3988.33 ± 207.37 0.45 ± 0.04 -4.98 ± 0.31 
7.50E+06 5557.33 ± 344.92 0.53 ± 0.01 1.24 ± 0.37 
1.00E+07 637.43 ± 71.21 0.6 ± 0.02 15.63 ± 0.32 
BV-luc-Lipofectamine 2000 
  1.00E+05 544.77 ± 24.58 0.46 ± 0.01 -16.73 ± 0.31 
1.00E+06 7007.33 ± 273.43 0.53 ± 0.02 -6.67 ± 0.19 
2.50E+06 8262 ± 868.88 0.65 ± 0.04 7.14 ± 0.41 
5.00E+06 2573 ± 87.5 0.87 ± 0.01 16.83 ± 0.42 
7.50E+06 644.47 ± 25.41 0.7 ± 0.13 20.87 ± 0.5 
1.00E+07 376.6 ± 37.35 0.65 ± 0.17 22.17 ± 0.42 
Table 5.1. Characterization of uncoated/cationic lipid coated BV-luc for size and 
zeta potential. Cationic lipids – Cellfectin II and Lipofectamine 2000 complexed with BV-
luc (1e4 – 1e7 molecules/BV particle) for 30 minutes and uncoated BV-luc particles were 
measured for size and zeta potential. Note the increase in the charge and size of rBV 
upon addition of increasing amounts of cationic lipids. Also note the fall in size of the 
complexes with increasing amounts of cationic lipids due to the electrostatic repulsion 




5.4. Cytotoxicity of cationic lipid coated BV 
Cellfectin II, as a transfection reagent, is known to have low cytotoxicity compared 
to most other cationic lipid based transfection reagents whereas Lipofectamine 2000 is 
relatively more cytotoxic to mammalian cells. Therefore, it was important to test the 
cytoxicity of these cationic lipids coated BV-luc on mammalian cells. Consistent with our 
previous studies, BV transduction did not result in significant cytotoxicity on cultured U87 
cells at MOI up to 100. Even at MOI 500, the cell viability decreased only to ~62% (Figure 
5.2). BV coated with varying amounts (105-107 molecules/per virus particle) of Cellfectin II 
and Lipofectamine 2000 showed cell viability not less than 57% even at at MOIs 500. 
5.5. Effect of cationic lipids on BV transduction 
Lipofectamine 2000 and Cellfectin II have been reported to improve adenoviral 
infection efficiency of several cell lines including primitive human hematopoietic cells (Byk 
et al., 1998). To test if the cationic lipid coating has a similar effect on BV transduction of 
U87 cells, BV-luc coated with varying amounts of cationic lipids (104 – 107 particles/BV) for 
30 minutes were added to U87 cells. Based on the cytotoxicity assay performed, BV-luc 
of MOI 50 was used for this study. Luciferase activities were measured after 48 hours. No 
significant alterations were noted in luciferase expression when Cellfectin II of 
concentration up to 106 molecules/BV particle and Lipofectamine 2000 of concentration up 
to 2.5x106 molecules/BV were used. However, beyond these concentrations, coating with 
Cellfectin II and Lipofectamine 2000 significantly reduced luciferase expression (Figure 
5.3). Thus, these results show that cationic lipids do not improve but interfere with the 




Figure 5.2. Cytotoxicty of Cellfectin II (A) and Lipofectamine 2000 (B) coated BV-luc 
on U87 glioma cells. Cellfectin II and Lipofectamine 2000 (1e4 – 1e7 molecules/BV 
particle) molecules complexed with BV-luc of MOI 50, 100 and 500 for 30 minutes were 
added to U87 cells and the % viability was measured after 48 hours.  Values are shown 
as mean ± SD of at least 3 wells. 

























Figure 5.3. Effect of cationic lipids coating on BV-luc transduction of U87 cells. BV-
luc complexed with varying amounts of Cellfectin II and Lipofectamine 2000 for 30 
minutes were added to U87 cells and luciferase gene expression was measured after 48 
hours. The values are represented as mean ± SD of at least 3 readings. Statistical 
analysis was done by one way ANOVA followed by Tukey’s multiple comparison tests. † - 
p < 0.05; ¥ - p < 0.01; * - p < 0.001. 
5.6. Serum protective effect of cationic lipids on BV 
Several reports have been published to demonstrate that BV is inactivated by the 
serum complement system (Sandig et al., 1996, Hofmann et al., 1998, Hofmann et al., 
1999, Kaikkonen et al., 2011). Significant reduction in BV transduction efficiencies were 
especially observed with sera from humans, rats and guinea pigs (Tani et al., 2003). 
These results were confirmed when the luciferase expression by U87 cells upon 
transduction with BV-luc significantly decreased in the presence of human (by ≈ 1000 

















































the serum protective effect of cationic lipids on BV was tested against rat and human 
serum in subsequent experiments. 
 
Figure 5.4. Effect of serum on BV transuction in U87 cells. BV-luc treated with sera 
from mouse, rat and human for 30 minutes at 37 ºC were added to U87 cells. Transgene 
expression was measured after 48 hours. Values are presented as Mean ± SD. Note the 
considerable decrease in transgene expression upon treatment of BV-luc with rat and 
human serum. Statistical analysis were carried out by one-way ANOVA followed by 
Tukey’s multiple comparison test. * - P value < 0.001 against no serum treated sample. 
To examine whether cationic lipids – Cellfectin II and Lipofectamine 2000 coated 
BV-luc offered better transduction in the presence of serum complement system, BV 
coated with varying amounts of these lipids (104-107 molecules/per virus particle) 
preincubated with 50% human/rat serum were assayed for luciferase expression in U87 
cells after 48 hours. Based on the cytotoxicity assay performed, MOI 50 was chosen to 
study the serum protective effect. Luciferase expression that reduced by ≈ 1000 fold in the 
presence of human serum and ≈ 500 fold in the presence of rat serum gradually 
increased with the increase in the amount of cationic lipid used for coating BV. Cellfectin II 
coating increased the transduction efficiency significantly between concentrations 2.5x106 
and 7.5x106/BV particle reaching the maximum increase of ≈ 24 fold at 5x106/BV particle 
in the presence of human serum. In the presence of rat serum, the transduction efficiency 
significantly increased between 1x106 and 2.5x106/BV particle reaching the maximum 
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increase of ≈ 180 fold at 2.5x106/BV particle (Figure 5.5). Lipofectamine 2000 coating 
increased the transduction efficiency significantly between concentrations 1x106 and 
5x106/BV particle by ≈ 10 fold in the presence of human serum whereas in the presence 
of rat serum, the transduction efficiency significantly increased at 1x106 by ≈ 13 fold 
(Figure 5.5). Thus, Cellfectin II coated on rBV at a concentration of 2.5x106/BV particle 
and Lipofectamine 2000 coated on rBV at a concentration of 1x106/BV particle offered the 
maximum serum protective effect in the presence of human and rat sera and  Cellfectin II 
was observed to offer better protection to rBV than Lipofectamine 2000 from the serum 
complement system in vitro. 
To gain insights in to the morphological changes that occurred upon coating rBV 
with cationic lipids and how the coating offers serum protective effect, transmission 
electron microscopy (TEM) was used (Figure 5.6). Coating ratio of 2.5x106 molecules of 
the cationic lipids/BV particle that offered maximum serum protective effect on BV in vitro 
and 50% human serum were chosen for this investigation against uncoated BV. Electron 
micrographs of the uncoated, no-serum treated samples displayed rod shaped particles of 
length 200-250 nm and width ≈ 50 nm complying with BV dimensions in the literature. 
Human serum treated uncoated BV samples were observed to have slightly swollen, 
distorted and disrupted envelope structure providing evidence for the action of 
complement proteins on BV. When BV coated with cationic lipids did not differ much in 
morphology from the uncoated BV, serum-treated, Cellfectin II and Lipofectamine 2000 
coated BV seemed to have an extra uneven layer around the normal rod shaped 
morphology and an increase in size. This may be due to the coating of cationic lipids on to 
rBV thus, suggesting that cationic lipid coating provided protection against complement-




Figure 5.5. Serum Protective effect of cationic lipids on BV-luc. Uncoated and 
cationic lipid coated BV-luc were pre-treated with (A) human and (B) rat serum and tested 
for transduction efficiency against no-serum treated sample. Luciferase activities were 
measured after 48 hours. Note the increase in the luciferase expression peaking at 
2.5x106 molecules of Cellfectin II/BV particle and at 1x106 molecules of Lipofectamine 
2000/BV particle in the presence of human and rat sera. The values are represented as 
Mean ± SD of atleast three values. Statistical analysis was done by one way ANOVA 
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Figure 5.6. Transmission electron microscopic analysis of uncoated/coated rBV 
without or with serum treatment. Uncoated no serum treated rBV showed clear rod-
shaped particles with dimensions, 200 – 250 nm in length and 50 nm in width whereas 
uncoated serum treated BV showed rod shaped BV particles with disrupted envelope 
(upper panel). Cationic lipid coated BV showed similar morphology like uncoated rBV 
whereas serum treated cationic lipid coated rBV showed increase in size and an extra 
layer around the rod shape indicating the efficient coating and protection from serum 




One of the major obstacles that hinder the progress of BV into clinical trials is its 
inactivation mediated by the complement system in the blood (Hofmann et al., 1998) and 
organs (Hofmann et al., 1995, Sandig et al., 1996). To prevent this, rBV has been used to 
deliver genes to immune privileged sites like eye, brain and testis or used in ex vivo 
transduction of cells and tissues. However, to fully exploit the advantages associated with 
BV, strategies to improve their serum resistance of BV need to be devised and this 
chapter addressed this issue. The major findings of this study include the following: firstly 
there is a strong electrostatic interaction between recombinant BV vectors and the 
cationic lipids – Lipofectamine 2000 and Cellfectin II which can be tapped to optimize the 
size of the virus-cationic lipid complex. Secondly, in the absence of serum complement, 
the coating of these cationic lipids on rBV does not improve the transgene expression but 
at higher concentrations, negatively affect it. Thirdly, in the presence of 50% serum 
complement in vitro, cationic lipid coating augment the transgene expression thus, 
demonstrating the suitability of using cationic lipids with baculoviruses for enhanced gene 
delivery in the presence of serum complement in vitro and opening up the possibility to 
test them in vivo.  
Cationic lipids and polymers have widely been used for in vitro and in vivo non-
viral gene delivery. Several gene delivery protocols using cationic lipids have entered 
clinical trials (summarized in Zhang et al., 2012). Among them, lipofectamine has been 
reported as vectors for gene transfer in vivo in blood vessels (Muller et al., 1994) and 
cerebral arteries (Toyoda et al., 2001) and is involved in almost 7% of the world wide 
gene therapy trials (Zhang et al., 2012). Also, Lipofectamine 2000 and Cellfectin II have 
been improvised to deliver genes in vitro in the presence of serum. Therefore, we 
reasoned that merging BVs and cationic lipids will result in hybrid vectors possessing 
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advantages of both. Because this strategy involved no genetic modifications but exploited 
the electrostatic interaction between the cationic lipids and BV, the fear of reduced 
transduction efficiency was almost eliminated.  
Of the two cationic lipids used, Cellfectin II was observed to form complexes of 
smaller diameter compared to Lipofectamine 2000. These could be attributed to the 
smaller size of the hydrophobic region of Cellfectin II compared to Lipofectamine 2000 
and higher charge of +4 at the cationic end that aids in its strong and tight binding to BV. 
Both the cationic lipids neither seemed to affect nor improve the transduction efficiency 
much at lower concentrations but affected the transduction efficiency negatively at higher 
concentrations (> 5x106 molecules/BV particle). This could be because the extremely high 
concentration of cationic lipids may be toxic to the cells (Figure 5.2) or may result in 
aggregation of virus particles (Table 5.1) making it difficult for them to enter the cells. 
Similar problems have been reported with cationic lipid coated adenovirus (Toyoda et al., 
2001). Hence, it was important to characterize the cationic lipid coated BV for optimal 
transduction efficiency. 
In the presence of serum complement, Cellfectin II seemed to offer better 
transgene expression than Lipofectamine 2000. One of the reasons for this could be 
differences in the route of entry of cationic lipid coated BV. Cellfectin II as a gene delivery 
vector enters the cells via a direct route through the cell cytosol (Wagner et al., 1993) as 
opposed to endocytosis by lipofectamine.  Transmission electron micrographs to gain 
insight into the morphological changes that occur upon serum complement treatment 
revealed similar morphology (increased size and presence of cationic lipid coating) for 
Lipofectamine 2000 and Cellfectin II coated BV. However, it does not provide any 
information about whether cationic lipid coating brought about any changes in the 
pathway of uptake of BV. Further in vitro experiments blocking the usual routes of BV 
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intake and cyro TEM will help gain better insight into the mechanism behind serum 
protective effect of cationic lipids.  Furthermore, since BV is capable of eliciting innate and 
adaptive immune responses (Abe et al., 2010) that have been tapped to produce BV-
based vaccines (Madhan et al., 2010), it is worth investigating whether modification of rBV 
with these cationic lipids can suppress cellular and humoral immune responses and add 
to the biosafety profile of BV like how the polyethylene glycol (Kreppel et al., 2008) 
coating modified responses to intravenously delivered adenoviruses.  
In summary, rBV coated with cationic lipids can effectively escape complement-
mediated inactivation in vitro to qualify as an efficient gene transfer vector in an 
environment containing complement components. With further evidences of its success in 
vivo, this simple technique of coating with biomaterial will aid in overcoming other hurdles 
to BV gene delivery such as elicitation of immune responses thus reinforcing the 
applications of BV in clinical gene therapy. 
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6. Conclusion  
The prime objective of this thesis is to understand the host responses to 
baculovirus in the brains of mice and macaques and develop methods to mask them from 
the host immune system. The main findings of this study include the following - (1) 
immune responses reduce with the reduction in the impurities of BV formulation (2) BV 
can mount antiviral immune responses in the brains which are generally considered to be 
immune privileged organs and (3) cationic lipid coating can effectively camouflage BV 
from the host complement system in vitro.  
In chapter 3, it was demonstrated that membrane chromatography purification 
method (MC+HS) offered in vivo grade BV formulation. In comparison with the widely 
used laboratory method of purifying baculovirus - high speed centrifugation, though the 
yield was lesser by MC+HS (≈ 30% against ≈ 55% from HS), purity was highly improved 
and there was little or no compromise in the transducing ability of BV. Scaling up of this 
method to purify large volumes of BV will be tested in the near future. The cDNA 
microarray gene expression profiling to investigate the immune responses elicited by BV 
prepared by the two methods – MC+HS and HS provided evidence in support of MC+HS 
method for providing in vivo grade BV formulation. The humongous data generated from 
the microarray studies also offered insights into the various means of IFN induction and 
production in mouse brains.  
In chapter 4, the first evidence for antiviral immune responses in macaque brains 
to BV was demonstrated by high throughput cDNA gene expression profiling. BV 
inoculation brought about significant changes in the expression of fewer number of probes 
(205 or 0.39% of all probes on the microarray chip) compared to mice brains (379 or 0.84 
of all probes on the microarray chip) suggesting that BV inoculation might not elicit 
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stronger immune responses in non-human primates than in rodents. Further experiments 
to test the host responses by varying the dose and time of observation can further our 
knowledge about the responses in non-human primates’ brain to BV inoculation. 
Significant fold changes in the genes belonging to RIG-1 like receptor signaling pathway 
but not other PRR signaling pathways in BV inoculated macaque brains compared to the 
control injected macaque brains suggests RIG-1 like receptor signaling to be the major 
pathway of IFN induction. The effects of higher doses or repeated doses of BV on eliciting 
other IFN induction pathways are yet to be studied.  Findings from the toxicology studies 
demonstrate the safety profile of BV for use as gene delivery vectors in higher animal 
models.   
In chapter 5, methods to avoid the most common problem of complement 
mediated BV inactivation were developed. rBV coated with cationic lipids – lipofectamine 
2000 and cellfectin II were demonstrated to effectively escape complement-mediated 
inactivation in vitro to qualify as an efficient gene transfer vector in an environment 
containing complement components. With further evidences of its success in vivo, this 
simple technique of coating with biomaterial will aid in overcoming other hurdles to 
baculovirus gene delivery such as elicitation of immune responses thus reinforcing the 
applications of baculovirus in clinical gene therapy. 
To conclude, the findings from this thesis help in gaining better understanding of 
BV responses in rodent and non-human primate brains that would allow for the facilitation 
of optimization of baculoviral vector design to escape the hurdles and successfully deliver 
genes into the CNS and also serve as a guide to rational therapeutic applications of 
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